U.S. patent application number 10/964379 was filed with the patent office on 2005-03-03 for two-phase, water-absorbent bioadhesive composition for delivery of an active agent to a patient.
Invention is credited to Bairamov, Danir F., Cleary, Gary W., Feldstein, Mikhail M., Kulichikhin, Valery G..
Application Number | 20050048103 10/964379 |
Document ID | / |
Family ID | 23105426 |
Filed Date | 2005-03-03 |
United States Patent
Application |
20050048103 |
Kind Code |
A1 |
Cleary, Gary W. ; et
al. |
March 3, 2005 |
Two-phase, water-absorbent bioadhesive composition for delivery of
an active agent to a patient
Abstract
An adhesive composition is provided that contains both a
hydrophobic phase and a hydrophilic phase, wherein the hydrophobic
phase is composed of a crosslinked hydrophobic polymer composition
and the hydrophilic phase is a water-absorbent blend of a
hydrophilic polymer and a complementary oligomer capable of
crosslinking the hydrophilic polymer through hydrogen bonding,
ionic bonding, and/or covalent bonding. The composition is useful
as a bioadhesive, for affixing drug delivery systems, wound
dressings, bandages, cushions, or the like to a body surface such
as skin or mucosal tissue.
Inventors: |
Cleary, Gary W.; (Los Altos
Hills, CA) ; Feldstein, Mikhail M.; (Moscow, RU)
; Kulichikhin, Valery G.; (Moscow, RU) ; Bairamov,
Danir F.; (Moscow, RU) |
Correspondence
Address: |
REED INTELLECTUAL PROPERTY LAW GROUP
800 MENLO AVENUE, SUITE 210
MENLO PARK
CA
94025
US
|
Family ID: |
23105426 |
Appl. No.: |
10/964379 |
Filed: |
October 12, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10964379 |
Oct 12, 2004 |
|
|
|
10137196 |
May 1, 2002 |
|
|
|
6803420 |
|
|
|
|
60288024 |
May 1, 2001 |
|
|
|
Current U.S.
Class: |
424/448 |
Current CPC
Class: |
A61K 9/7053 20130101;
A61L 15/585 20130101; C08L 33/08 20130101; C08L 2312/00 20130101;
C08L 71/00 20130101; C08L 2666/20 20130101; A61L 15/44 20130101;
C08L 23/22 20130101; A61L 15/60 20130101; C09J 123/22 20130101;
C09J 123/22 20130101; C08L 2666/20 20130101; A61L 15/46 20130101;
A61L 15/585 20130101; C08L 77/00 20130101 |
Class at
Publication: |
424/448 |
International
Class: |
A61F 013/02; A61L
015/16 |
Claims
We claim:
1. A composition for delivery of an active agent to a human
patient, comprising an effective amount of an active agent loaded
into a bioadhesive composition comprising a hydrophobic phase and a
hydrophilic phase, wherein the hydrophobic phase comprises a
crosslinked hydrophobic polymer composition and the hydrophilic
phase comprises a mixture of a hydrophilic polymer and a
complementary oligomer capable of crosslinking the hydrophilic
polymer through hydrogen bonding, ionic bonding, or covalent
bonding.
2. The composition of claim 1, wherein the active agent is a
locally acting, topically administrable agent.
3. The composition of claim 2, wherein the active agent is selected
from bacteriostatic agents, bacteriocidal agents, antibiotic
agents, pain-relieving agents, antifungal agents, keratolytic
agents, vesicants, and anti-acne agents.
4. A topical pharmaceutical formulation comprising the composition
of claim 2 and a pharmaceutically acceptable topical carrier.
5. The composition of claim 1, wherein the active agent is a
systemically active agent.
6. The composition of claim 5, wherein the active agent is selected
from: analeptic agents; analgesic agents; anesthetic agents;
antiarthritic agents; respiratory drugs; anticancer agents;
anticholinergics; anticonvulsants; antidepressants; antidiabetic
agents; antidiarrheals; antihelminthics; antihistamines;
antihyperlipidemic agents; antihypertensive agents; anti-infective
agents; antinflammatory agents; antimigraine preparations;
antinauseants; antiparkinsonism drugs; antipruritics;
antipsychotics; antipyretics; antitubercular agents; antiulcer
agents; antiviral agents; anxiolytics; appetite suppressants;
attention deficit disorder (ADD) and attention deficit
hyperactivity disorder (ADHD) drugs; calcium channel blockers;
antianginal agents; central nervous system (CNS) agents;
beta-blockers; antiarrhythmic agents; cough and cold preparations;
diuretics; genetic materials; herbal remedies; hormonolytics;
hypnotics; hypoglycemic agents; immunosuppressive agents;
leukotriene inhibitors; mitotic inhibitors; muscle relaxants;
narcotic antagonists; nicotine; nutritional agents; ophthalmic
drugs; parasympatholytics; peptide drugs; psychostimulants;
sedatives; steroids; smoking cessation agents; tranquilizers; and
vasodilators.
7. An improved delivery system composed of an active agent
reservoir, a backing layer laminated thereto, and an integral means
for affixing the system to the body surface, wherein the
improvement comprises formulating the active agent reservoir from
the composition of claim 1.
8. The composition of claim 1, wherein the crosslinked hydrophobic
polymer composition is a crosslinked butyl rubber.
9. The composition of claim 2, wherein the crosslinked hydrophobic
polymer composition is butyl rubber crosslinked with
polyisobutylene.
10. The composition of claim 1, wherein the hydrophilic polymer and
the complementary oligomer are covalently crosslinked.
11. The composition of claim 1, wherein the hydrophilic polymer is
selected from the group consisting of poly(N-vinyl lactams),
poly(N-vinyl amides), poly(N-alkylacrylamides), polyacrylic acid,
polymethacrylic acid, polyvinyl alcohol, polyvinylamine, and
copolymers and blends thereof.
12. The composition of claim 1 1, wherein the hydrophilic polymer
is selected from the group consisting of poly(N-vinyl lactams),
poly(N-vinyl amides), poly(N-alkylacrylamides), and copolymers and
blends thereof.
13. The composition of claim 12, wherein the hydrophilic polymer is
a poly(N-vinyl lactam).
14. The composition of claim 13, wherein the hydrophilic polymer is
a poly(N-vinyl lactam) homopolymer.
15. The composition of claim 14, wherein the poly(N-vinyl lactam)
is selected from the group consisting of polyvinyl pyrrolidone,
polyvinyl caprolactam, and blends thereof.
16. The composition of claim 15, wherein the poly(N-vinyl lactam)
is polyvinyl pyrrolidone.
17. The composition of claim 15, wherein the poly(N-vinyl lactam)
is polyvinyl caprolactam.
18. The composition of claim 1, wherein the hydrophilic polymer has
a number average molecular weight in the range of approximately
20,000 to 2,000,000.
19. The composition of claim 18, wherein the hydrophilic polymer
has a number average molecular weight in the range of approximately
200,000 to 1,000,000.
20. The composition of claim 1, wherein the complementary oligomer
has a molecular weight in the range of about 45 to 800.
21. The composition of claim 20, wherein the complementary oligomer
has a molecular weight in the range of about 45 to 600.
22. The composition of claim 21, wherein the complementary oligomer
has a molecular weight in the range of about 300 to 600.
23. The composition of claim 1, wherein the complementary oligomer
is selected from the group consisting of polyalcohols, monomeric
and oligomeric alkylene glycols, polyalkylene glycols,
carboxyl-terminated polyalkylene glycols, amino-terminated
polyalkylene glycols, ether alcohols, alkane diols and carbonic
diacids.
24. The composition of claim 23, wherein the complementary oligomer
is selected from the group consisting of polyalkylene glycols and
carboxyl-terminated polyalkylene glycols.
25. The composition of claim 24, wherein the complementary oligomer
is selected from the group consisting of polyethylene glycol and
carboxyl-terminated polyethylene glycol.
26. The composition of claim 25, wherein the complementary oligomer
is polyethylene glycol.
27. The composition of claim 26, wherein the complementary oligomer
is polyethylene glycol 400.
28. An implantable dosage form comprising the composition of claim
1.
29. An oral dosage form comprising the composition of claim 1.
30. A transmucosal dosage form comprising the composition of claim
1.
31. A method for delivering an active agent comprising applying the
composition of claim 1 to an individual's body surface.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a divisional of U.S. patent application Ser. No.
10/137,196, filed May 1, 2002, now U.S. Pat. No. 6,803,420, which
claims priority under 35 U.S.C. .sctn.119(e)(1) to provisional U.S.
Patent Application Ser. No. 60/288,024, filed May 1, 2001 and
application Ser. No. 10/137,196, filed May 1, 2002, now U.S. Pat.
No. 6,803,420, issued on even date herewith.
TECHNICAL FIELD
[0002] This invention relates generally to adhesive compositions,
and more particularly relates to a novel adhesive composition
composed of a hydrophobic phase and a hydrophilic phase. The
composition is useful as a bioadhesive in a variety of contexts
involving application of a drug delivery system, wound dressing,
cushion, or the like to an individual's skin or other body
surface.
BACKGROUND
[0003] Pressure-sensitive adhesives (PSAs) for application to the
skin or other body surface are well known and have been used for
many years in a variety of consumer and medical applications.
Pressure-sensitive adhesives are characterized as being normally
tacky and exhibiting instant tack when applied to a substrate. Many
polymers have been used to manufacture pressure-sensitive adhesives
as, for example, acrylic and methacrylic ester homo- or copolymers,
butyl rubber-based systems, silicones, urethanes, vinyl esters and
amides, olefin copolymer materials, natural or synthetic rubbers,
and the like. All the PSAs are elastomers, i.e. they exhibit
viscoelastic properties typical of rubbers.
[0004] Existing examples of pressure-sensitive adhesives used for
affixing a drug delivery system, cushion, or the like to the skin
include polysiloxanes (e.g., polydimethyl siloxanes, polydiphenyl
siloxanes, and siloxane blends), polyisobutylenes, polyacrylates,
acrylic acid-acrylate copolymers (e.g., copolymers of acrylic acid
copolymers with 2-ethylhexyl acrylate or isooctyl acrylate), and
tacky rubbers such as polyisobutene, polybutadiene,
polystyrene-isoprene copolymers, polystyrene-butadiene copolymers,
and neoprene (polychloroprene). All of these PSAs are hydrophobic
polymers and their common disadvantage is a loss in adhesion toward
hydrated substrates.
[0005] "Bioadhesion" is defined as a pressure-sensitive adhesion
with respect to highly hydrated biological tissues such as mucosal
tissue. In contrast to conventional pressure sensitive adhesives
such as rubber, polysiloxanes, and acrylates that adhere mainly to
dry substrates, bioadhesives (BAs) exhibit good tack when adhered
to hydrated biological substrates. To be bioadhesive, water should
provide a plasticizing effect on a polymer, i.e., the polymer
should be hydrophilic. For example, the range of typical BAs
includes slightly cross-linked polyacrylic and polymethacrylic
acids (EP 0 371 421) as well as blends of hydrophilic cellulose
derivatives (40-95%) with polyethylene glycol (PEG) (U.S. Pat. No.
4,713,243).
[0006] Bioadhesives become tacky as the crosslinked polymer swells
in significant quantities of water. The cohesive strength of highly
swollen hydrophilic polymers is generally low and the BAs thus
differ from the PSAs in this regard.
[0007] Attempts to combine the properties of PSAs and BAs have been
described by Biegajski et al. in U.S. Pat. No. 5,700,478, where a
water-soluble pressure-sensitive mucoadhesive was obtained by
blending 95-40% polyvinylpyrrolidone (PVP) with 0-50% hydroxypropyl
cellulose (HPC) and 11-60% glycerol. Other examples of hydrophilic
polymer blends coupling the properties of PSAs and BAs involve
polyacrylic acid-polyvinyl alcohol (PAA-PVA) interpolymeric
complexes formed by hydrogen bonding between the monomer units of
the complementary polymer chains and plasticized with PEG-200,
glycerol or polypropylene glycol (PPG), molecular weight 425 g/mol
(German Patent Application No. DE 42 19 368).
[0008] The ideal performance characteristics of an adhesive
composition intended for use on human skin and/or mucosal tissue
present difficult and conflicting technical requirements.
Initially, the adhesive should be suitable for long-term skin
contact, and permeable to and physically and chemically compatible
with any active agent and any permeation enhancers or other
vehicles or additives that are present. The ideal adhesive should
also be nonirritating, noncomedogenic and nonsensitizing, yet bond
quickly to skin or mucosal tissue at the intended site of use with
only very slight pressure. The adhesive should maintain its bond
for as long a period of time as necessary and be resistant to
inadvertent removal, yet be easily removed without removing any
skin or leaving a residue (a suitable strength of an adhesive joint
with the skin ranges from about 200 to 400 N/m under the 180 degree
peel test). Furthermore, the adhesive composition should not be
sensitive to or degradable by exposure to moisture or high
humidity.
[0009] With bioadhesives, hydrophilic compositions are preferred
for the adhesive compositions to adhere well to moist substrates.
Hydrophilic adhesives are advantageous in other respects as well,
insofar as:
[0010] (1) hydrophilic adhesives can provide greater adhesion
compared with hydrophobic adhesives, because the surface energy of
hydrophilic adhesives is typically higher and closer to that of
biological substrates such as skin and mucosal membranes;
[0011] (2) hydrophilic adhesives are compatible with a wide variety
of drugs, excipients and additives;
[0012] (3) the plasticizing effect of water sorbed by hydrophilic
adhesives from hydrated skin or mucosal tissues enhances adhesion,
in contrast to hydrophobic adhesives;
[0013] (4) the enhanced solubility of drugs in hydrophilic
adhesives facilitates control over drug release kinetics;
[0014] (5) with hydrophilic adhesives, based on hydrophilic
polymers, there is an expanded capability to control and manipulate
the adhesive-cohesive balance; and
[0015] (6) the adhesive properties of hydrophilic polymers are
considerably less sensitive to their molecular weight than those of
hydrophobic polymers, as a result of specific intramolecular and
intermolecular interaction within hydrophilic adhesives.
[0016] In order to increase the hydrophilicity of an adhesive
composition, hydrophobic PSAs have been "hydrophilized" by
incorporation of non-tacky hydrophilic polymers and fillers into a
hydrophobic adhesive. Thus, polyisobutylene (PIB) PSA has been
hydrophilized by incorporation of cellulose and cellulose
derivatives (U.S. Pat. No. 4,231,369), polyvinyl alcohol (PVA),
pectin and gelatin (U.S. Pat. Nos. 4, 367,732 and 4,867,748), and
SiO.sub.2 (U.S. Pat. No. 5,643,187). Rubber adhesives have also
been modified by filling with amphiphilic surfactants, or by
treating the PSA polymer with a plasma-oxygen discharge. Acrylic
PSAs can be hydrophilized by incorporation of PVP (U.S. Pat. No.
5,645,855). Hydrophilization of hydrophobic adhesives, while
somewhat effective, tends to result in a partial loss of
adhesion.
[0017] There is, accordingly, a need in the art for improved
bioadhesive compositions that combine the properties of hydrophobic
PSAs with the many advantages of hydrophilic adhesive compositions.
It would also be ideal if such an adhesive composition could be
adapted for a variety of uses, e.g., in wound healing and bandages,
in the fabrication of transdermal and other drug delivery systems,
in preparing medicated adhesive formulations for topical and
transdermal pharmaceutical formulations, in pressure-relieving
cushions (which may or may not be medicated), as sealants for
ostomy devices and prostheses, as conductive adhesives for
attachment of electroconductive articles such as electrodes to the
skin, and the like.
SUMMARY OF THE INVENTION
[0018] It is a primary object of the invention to provide a novel
adhesive composition that meets all of the above-discussed needs in
the art.
[0019] In one embodiment, the invention pertains to a two-phase,
water-absorbent adhesive composition that comprises a blend of a
hydrophobic pressure-sensitive adhesive with a water-absorbent
hydrophilic composition. As such, the composition comprises a
hydrophobic phase and a hydrophilic phase, wherein the hydrophobic
phase includes a hydrophobic polymer, e.g., a crosslinked
hydrophobic polymer, preferably a hydrophobic PSA, and the
hydrophilic phase comprises a blend of a relatively high molecular
weight hydrophilic polymer and a lower molecular weight
complementary oligomer that is capable of crosslinking the
hydrophilic polymer through hydrogen bonds, and optionally through
covalent and/or ionic bonds as well. The weight ratio of the
hydrophilic polymer to the complementary oligomer is selected to
optimize the adhesive strength, cohesive strength, and
hydrophilicity of the composition. The composition may additionally
include any number of additives, e.g., active agents, fillers,
tackifiers, and the like.
[0020] In another embodiment, a drug delivery system is provided
comprising an active agent in an adhesive composition as described
above, wherein the system has a body-contacting surface and an
outer surface, with the adhesive composition present within a
region of the body-contacting surface. The body-contacting surface
may be entirely comprised of the adhesive composition, or the
perimeter of the body-contacting surface may be composed of a
different skin contact adhesive. The drug delivery system may be
designed for systemic delivery of an active agent, e.g., via the
transdermal or transmucosal routes. The system may also be designed
for topical administration of a locally active agent.
[0021] In a related embodiment, a wound dressing is provided
comprised of a substrate for application to the wound region,
wherein the substrate has a body-contacting surface and an outer
surface, with the adhesive composition present in a
wound-contacting region of the body-contacting surface. As with
drug delivery systems, the body-contacting surface may be entirely
comprised of the adhesive composition, although it is preferred
that the composition be present in a central region on the
body-contacting surface, with the perimeter of the body-contacting
surface composed of a different skin contact adhesive. In this
embodiment, absorption of water present in the wound exudate
gradually causes the wound dressing to lose tack.
[0022] The adhesive compositions herein are also useful in a host
of additional applications, e.g., in various types of
pharmaceutical formulations, pressure-relieving cushions (which may
or may not be medicated), bandages, ostomy devices, prosthesis
securing means, face masks, sound, vibration or impact absorbing
materials, and the like. Also, the compositions may be rendered
electrically conductive by incorporation of an electrically
conductive material, and may thus be used for attaching an
electroconductive article, such as an electrode (e.g., a
transcutaneous electric nerve stimulation, or "TENS" electrode, an
electrosurgical return electrode, or an EKG monitoring electrode),
to an individual's body surface.
[0023] The adhesive compositions of the invention provide a number
of significant advantages relative to the prior art. In particular,
the present compositions:
[0024] (1) may be fabricated so as to display very high swelling
upon contact with water without concomitant loss of adhesion;
[0025] (2) can be fabricated so as to exhibit little or no cold
flow during use;
[0026] (3) are useful and versatile bioadhesives in a number of
contexts, including wound dressings, active agent delivery systems
for application to a body surface, pressure-relieving cushions, and
the like; and
[0027] (4) are readily modified during manufacture so that
properties such as adhesive strength, cohesive strength,
absorption, and swelling can be optimized.
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] FIG. 1 schematically illustrates one embodiment of a wound
dressing prepared with an adhesive composition of the invention,
wherein the dressing is composed of an outwardly facing backing
layer and a body-facing skin contact adhesive layer laminated
thereto, wherein an adhesive composition of the invention is
present as a film on an interior region of the body-contacting
surface of the skin contact adhesive layer.
[0029] FIG. 2 schematically illustrates an alternative embodiment
of a wound dressing of the invention that does not include separate
backing and skin contact adhesive layers, wherein a backing layer
is composed of a skin contact adhesive having a nontacky outwardly
facing surface and a slightly tacky body facing surface, and an
adhesive composition of the invention is present as a film on an
interior region of the body-contacting, at least slightly tacky
surface of the backing layer.
[0030] FIG. 3 schematically illustrates another embodiment of a
wound dressing of the invention, wherein the dressing is similar in
structure to that of FIG. 2, but includes a peripheral skin contact
adhesive on the body-contacting surface. In this case, the
body-contacting surface of the backing layer does not need to be
tacky.
[0031] FIG. 4 is a bottom plan view of the embodiment of FIG. 3
taken along the 4-4 lines of that figure, and illustrates the
concentric regions of the body-contacting surface, with a
peripheral skin contact adhesive surrounding an inner region of a
nontacky or slightly tacky material, which in turn contains the
adhesive composition in a central region intended as the
wound-contacting region.
[0032] FIG. 5 illustrates another embodiment of a wound dressing
herein wherein the three layers of a laminated composite, an
outwardly facing backing layer, an interior pressure sensitive
adhesive layer, and a body-contacting layer composed of an adhesive
composition of the invention, are coextensive.
[0033] FIG. 6 illustrates an analogous embodiment wherein the
interior pressure sensitive adhesive layer is omitted, and the
hydrogel-containing layer is made sufficiently tacky so that the
backing layer adheres directly thereto. Again, the backing layer
and the body-contacting hydrogel layer are co-extensive.
[0034] FIG. 7 shows the peel strength of PIB-BR blends pressed
between a polyethylene substrate.
[0035] FIG. 8 shows the effect of curing agent concentration and
temperature on the rheokinetics of PVP-PEG hydrogel thermal
crosslinking, as described in Example 2.
[0036] FIG. 9 illustrates the curing rheokinetics of
PIB-BR-Regalite mixtures with an incorporated PVP-PEG hydrogel, as
described in Example 2.
[0037] FIG. 10 shows the effect on the adhesion of PIB blends with
PVP-PEG and HPC, as evaluated in Example 3.
DETAILED DESCRIPTION OF THE INVENTION
[0038] I. Definitions and Nomenclature:
[0039] Before describing the present invention in detail, it is to
be understood that unless otherwise indicated this invention is not
limited to specific compositions, components or manufacturing
processes, as such may vary. It is also to be understood that the
terminology used herein is for the purpose of describing particular
embodiments only, and is not intended to be limiting. It must be
noted that, as used in this specification and the appended claims,
the singular forms "a," "an," and "the" include plural referents
unless the context clearly dictates otherwise. Thus, for example,
reference to "a hydrophilic polymer" includes not only a single
hydrophilic polymer but also a combination or mixture of two or
more different hydrophilic polymers, reference to "a plasticizer"
includes a combination or mixture of two or more different
plasticizers as well as a single plasticizer, and reference to "a
hydrophobic pressure-sensitive adhesive" includes a mixture of two
or more such adhesives as well as a single such adhesive, and the
like.
[0040] In describing and claiming the present invention, the
following terminology will be used in accordance with the
definitions set out below.
[0041] The definitions of "hydrophobic" and "hydrophilic" polymers
are based on the amount of water vapor absorbed by polymers at 100%
relative humidity. According to this classification, hydrophobic
polymers absorb only up to 1 wt. % water at 100% relative humidity
("rh"), while moderately hydrophilic polymers absorb 1-10% wt. %
water, hydrophilic polymers are capable of absorbing more than 10
wt. % of water, and hygroscopic polymers absorb more than 20 wt. %
of water.
[0042] The term "crosslinked" herein refers to a composition
containing intramolecular and/or intermolecular crosslinks, whether
arising through covalent or noncovalent bonding. "Noncovalent"
bonding includes both hydrogen bonding and electrostatic (ionic)
bonding.
[0043] The term "polymer" includes linear and branched polymer
structures, and also encompasses crosslinked polymers as well as
copolymers (which may or may not be crosslinked), thus including
block copolymers, alternating copolymers, random copolymers, and
the like. Those compounds referred to herein as "oligomers" are
polymers having a molecular weight below about 1000 Da, preferably
below about 800 Da.
[0044] The term "hydrogel" is used in the conventional sense to
refer to water-swellable polymeric matrices that can absorb a
substantial amount of water to form elastic gels, wherein
"matrices" are three-dimensional networks of macromolecules held
together by covalent or noncovalent crosslinks. Upon placement in
an aqueous environment, dry hydrogels swell to the extent allowed
by the degree of cross-linking.
[0045] The term "water-insoluble" refers to a compound or
composition whose solubility in water is less than 5 wt. %,
preferably less than 3 wt. %, more preferably less than 1 wt. %
(measured in water at 20.degree. C.).
[0046] The term "active agent" is used herein to refer to a
chemical material or compound suitable for administration to a
human patient and that induces a desired beneficial effect, e.g.,
exhibits a desired pharmacological activity. The term includes, for
example, agents that are therapeutically effective,
prophylactically effective, and cosmetically (and cosmeceutically)
effective. Also included are derivatives and analogs of those
compounds or classes of compounds specifically mentioned which also
induce the desired beneficial effect.
[0047] By "transdermal" drug delivery is meant administration of a
drug to the skin surface of an individual so that the drug passes
through the skin tissue and into the individual's blood stream.
Unless otherwise indicated, the term "transdermal" is intended to
include "transmucosal" drug administration, i.e., administration of
a drug to the mucosal (e.g., sublingual, buccal, vaginal, rectal)
surface of an individual so that the drug passes through the
mucosal tissue and into the individual's blood stream.
[0048] The term "topical administration" is used in its
conventional sense to mean delivery of an active agent to a body
surface such as the skin or mucosa, as in, for example, topical
drug administration in the prevention or treatment of various skin
disorders, the application of cosmetics and cosmeceuticals
(including moisturizers, masks, sunscreens, etc.), and the like.
Topical administration, in contrast to transdermal administration,
provides a local rather than a systemic effect.
[0049] The term "body surface" is used to refer to any surface
located on the human body or within a body orifice. Thus, a "body
surface" includes, by way of example, skin, or mucosal tissue,
including the interior surface of body cavities that have a mucosal
lining. Unless otherwise indicated, the term "skin" as used herein
should be interpreted as including mucosal tissue and vice
versa.
[0050] Similarly, when the term "transdermal" is used herein, as in
"transdermal drug administration" and "transdermal drug delivery
systems," it is to be understood that unless explicitly indicated
to the contrary, both "transmucosal" and "topical" administration
and systems are intended as well.
[0051] II. Adhesive Compositions:
[0052] In a first embodiment, an adhesive composition is provided
that combines the properties of a hydrophobic PSA with the
advantages of a hydrophilic adhesive composition. The composition
is comprised of a hydrophobic phase and a hydrophilic phase,
wherein the hydrophobic phase includes at least one hydrophobic
polymer, and the hydrophilic phase, dispersed or otherwise
contained therein, is comprised of a mixture of a hydrophilic
polymer and a low molecular weight complementary oligomer capable
of hydrogen bonding thereto. The low molecular weight complementary
oligomer may also serve to crosslink the hydrophilic polymer via
ionic and/or covalent bonding.
[0053] A. The Hydrophobic Phase
[0054] The hydrophobic phase is comprised of at least one
hydrophobic polymer. The hydrophobic polymer is typically a
hydrophobic pressure-sensitive adhesive polymer, preferably a
thermosetting polymer. Preferred hydrophobic PSA polymers are
crosslinked butyl rubbers, wherein a "butyl rubber," as well known
in the art, is an isoprene-isobutylene copolymer typically having
an isoprene content in the range of about 0.5 to 3 wt. %, or a
vulcanized or modified version thereof, e.g., a halogenated
(brominated or chlorinated) butyl rubber. In a particularly
preferred embodiment, the hydrophobic PSA polymer is butyl rubber
crosslinked with polyisobutylene. Other suitable hydrophobic
polymers include, for example, natural rubber adhesives, vinyl
ether polymers, polysiloxanes, polyisoprene, butadiene
acrylonitrile rubber, polychloroprene, atactic polypropylene, and
ethylene-propylene-diene terpolymers (also known as "EPDM" or "EPDM
rubber") (available as Trilene.RTM. 65 and Trilene.RTM. 67 from
Uniroyal Chemical Co., Middlebury, Conn.). Still other suitable
hydrophobic PSAs will be known to those of ordinary skill in the
art and/or are described in the pertinent texts and literature.
See, for example, the Handbook of Pressure-Sensitive Adhesive
Technology, 2nd Ed., Satas, Ed. (New York: Von Nostrand Reinhold,
1989). Particularly preferred hydrophobic polymers are the
crosslinked butyl rubbers available in the Kalar.RTM. series from
Elementis Specialties, Inc. (Hightstown, N.J.), with Kalar.RTM.
5200, Kalar.RTM. 5215, Kalar.RTM. 5246, and Kalar.RTM. 5275 most
preferred.
[0055] For most applications, the crosslinked hydrophobic polymer
should have a sufficiently high degree of crosslinking so that the
composition does not exhibit cold flow following application to a
surface, e.g. a body surface such as skin. As will be appreciated
by those in the art, the degree of crosslinking correlates with
Mooney viscosity, a measure of the resistance of a raw or
unvulcanized rubber to deformation as measured in a Mooney
viscometer. A higher Mooney viscosity indicates a higher degree of
crosslinking. The Mooney viscosity of preferred hydrophobic PSAs
for use herein should be at least 20 cps at 25.degree. C., and will
generally be in the range of about 25 cps to 80 cps, preferably
about 30 cps to 75 cps, at 25.degree. C. The Mooney viscosities of
the preferred Kalar.RTM. series polymers herein are as follows:
Kalar.RTM. 5200, 40-45 cps; Kalar.RTM. 5215, 47-57 cps; Kalar.RTM.
5246, 30-40 cps; and Kalare 5275, 70-75.degree. C.).
[0056] The molecular weight of the hydrophobic PSA is not critical,
although the molecular weight will typically be less than about
100,000 Da. The amount of the polymer generally, although not
necessarily, represents in the range of about 5 wt. % to 15 wt. %,
preferably about 7.5 wt. % to 12 wt. %, most preferably about 7.5
wt. % to 10 wt. %, of the composition after drying.
[0057] Other hydrophobic polymers that may be used in place of or
in addition to the hydrophobic PSA include, without limitation,
hydrocarbon polymers such as polyethylene, acrylate polymers and
copolymers, polyacrylamides, polyurethanes, plasticized
ethylene-vinyl acetate copolymers, polyisobutylenes, polybutadiene,
and neoprene (polychloroprene). Additional hydrophobic polymers
suitable for incorporation into the hydrophobic phase are natural
and synthetic elastomeric polymers, including, for example, AB,
ABA, and "multiarmed" (AB).sub.x block copolymers, where for
example, A is a polymerized segment or "block" comprising
aryl-substituted vinyl monomers, preferably styrene, .alpha.-methyl
styrene, vinyl toluene, and the like, B is an elastomeric,
conjugated polybutadiene or polyisoprene block, and x has a value
of 3 or more. Preferred elastomers are butadiene-based and
isoprene-based polymers, particularly styrene-butadiene-styrene
(SBS), styrene-butadiene (SB), styrene-isoprene-styrene (SIS), and
styrene-isoprene (SI) block copolymers, where "S" denotes a
polymerized segment or "block" of styrene monomers, "B" denotes a
polymerized segment or block of butadiene monomers, and "I" denotes
a polymerized segment or block of isoprene monomers. Other suitable
elastomers include radial block copolymers having a SEBS backbone
(where "E" and "B" are, respectively, polymerized blocks of
ethylene and butylene) and I and/or SI arms. Natural rubber
(polyisoprene) and synthetic polyisoprene can also be used.
[0058] Commercially available hydrophobic elastomers include linear
SIS and/or SI block copolymers such as Quintac.RTM. 3433 and
Quintac.RTM. 3421, available from Nippon Zeon Company, Ltd. (U.S.
sales office--Louisville, Ky.); Vector.RTM. DPX 559, Vector.RTM.
4111 and Vector.RTM. 4113, available from Dexco, a partnership of
Exxon Chemical Co. (Houston, Tex.) and Dow Chemical Co. (Midland
Mich.); and Kraton.RTM. rubbers, such as Kraton 604x, Kraton
D-1107, Kraton D-1117, and Kraton D-1113, available from Shell
Chemical Co. (Houston, Tex.). Kraton D-1 107 is a predominantly SIS
elastomer containing about 15% by weight SI blocks. Kraton D-1320x
is an example of a commercially available (SI).sub.x I.sub.y
multiarmed block copolymer in which some of the arms are
polyisoprene blocks. Commercially available butadiene-based
elastomers include SBS and/or SB rubbers, such as Kraton D-1101,
D-1102 and D-1118X, from Shell Chemical Co.; Solprene.RTM. 1205, an
SB block copolymer available from Housemex, Inc. (Houston, Tex.);
and Kraton TKG-101 (sometimes called "Tacky G"), a radial block
copolymer having an SEBS backbone (E=ethylene block; B=butylene
block) and I and/or SI arms.
[0059] In a particularly preferred embodiment, the hydrophobic
phase is comprised of a butyl rubber, i.e., an isoprene-isobutylene
copolymer typically having an isoprene content in the range of
about 0.5 to 3 wt. %, crosslinked with polyisobutylene.
Crosslinking may be effected using curing processes known to those
of ordinary skill in the art and/or described in the pertinent
texts and literature, e.g., using radiation, chemical crosslinking,
and/or heat. However, a preferred process involves mixing the
polyisobutylene and the butyl rubber at a temperature in the range
of about 80.degree. C. to about 140.degree. C., followed by a
thermal cure at a higher temperature, generally in the range of
about 150.degree. C. to about 170.degree. C., in the presence of a
suitable curing agent and an organic peroxide or zinc oxide in
combination with zinc stearate or stearic acid. Preferably, the
reaction is carried out in the presence of an organic peroxide.
Suitable organic peroxides are generally selected from: dialkyl
peroxides such as t-butyl peroxide and
2,2-bis(t-butylperoxy)propane; diacyl peroxides such as benzoyl
peroxide and acetyl peroxide; peresters such as t-butyl perbenzoate
and t-butyl per-2-ethylhexanoate; perdicarbonates such as dicetyl
peroxy dicarbonate and dicyclohexyl peroxy dicarbonate; ketone
peroxides such as cyclohexanone peroxide and methylethylketone
peroxide; and hydroperoxides such as cumene hydroperoxide and
tert-butyl hydroperoxide. Curing agents for this process are those
compounds known in the art as vulcanizing agents for butyl rubber,
and thus include, without limitation, alkyl phenol-formaldehyde
resins, dicatechol borate salts (e.g., Permalux.RTM., the
di-ortho-tolylguanidine salt of dicatechol borate), (m-phenylene
bis maleimide, 2,4,6-trimercapto-5 triazine), zinc diethyl
dithiocarbamate and other dithiocarbamates, thiuram sulfides (e.g.,
Tetrone.RTM. A, dipentamethylene thiuram hexasulfide; and "TMTDS,"
tetramethyl thiuram disulfide) preferably in combination with
sulfur, alkylated phenol disulfides, and diphenyl phenylene diamine
(DPPD).
[0060] Preferred curing agents for the aforementioned process are
alkyl phenol-formaldehyde condensation resins. Such resins may be
halogenated, in which case the terminal methylol moieties of the
resin are halogenated, such that a halomethyl (e.g., a bromomethyl
or chloromethyl) group is present at each terminus. These resins
are ideal curing agents, insofar as the curing reaction is not
accompanied by formation of any volatile organic compounds. These
resins have the molecular structure 1
[0061] wherein n is typically an integer in the range of zero to 10
inclusive, X is hydroxyl or halo (typically bromo or chloro), R is
an alkyl group, generally having 1 to 10 carbon atoms, and L is a
lower alkylene or lower oxyalkylene linking group, preferably
--CH.sub.2-- or --CH.sub.2--O--CH.sub.2--. Methylol-terminated
compounds, wherein X is hydroxyl, are commercially available as,
for example, TACKIROL 201 (trade name, a product of Taoka Chemical
Co., Ltd.) and HITANOL 2501 (trade name, a product of Hitachi
Chemical Co., Ltd), while the dibromomethyl analog is available as
SP1055 from Schenectady Chemical Company.
[0062] B. The Hydrophilic Phase
[0063] The hydrophilic phase comprises a blend of a hydrophilic
polymer and a complementary oligomer capable of crosslinking the
hydrophilic polymer through hydrogen bonds, ionic bonds, and/or
covalent bonds. Suitable hydrophilic polymers include repeating
units derived from an N-vinyl lactam monomer, a carboxy vinyl
monomer, a vinyl ester monomer, an ester of a carboxy vinyl
monomer, a vinyl amide monomer, and/or a hydroxy vinyl monomer.
Such polymers include, by way of example, poly(N-vinyl lactams),
poly(N-vinyl acrylamides), poly(N-alkylacrylamides- ), substituted
and unsubstituted acrylic and methacrylic acid polymers, polyvinyl
alcohol (PVA), polyvinylamine, copolymers thereof and copolymers
with other types of hydrophilic monomers (e.g. vinyl acetate).
[0064] Poly(N-vinyl lactams) useful herein are preferably
noncrosslinked homopolymers or copolymers of N-vinyl lactam monomer
units, with N-vinyl lactam monomer units representing the majority
of the total monomeric units of a poly(N-vinyl lactams) copolymer.
Preferred poly(N-vinyl lactams) for use in conjunction with the
invention are prepared by polymerization of one or more of the
following N-vinyl lactam monomers: N-vinyl-2-pyrrolidone;
N-vinyl-2-valerolactam; and N-vinyl-2-caprolactam. Nonlimiting
examples of non-N-vinyl lactam comonomers useful with N-vinyl
lactam monomeric units include N,N-dimethylacrylamide, acrylic
acid, methacrylic acid, hydroxyethylmethacrylate, acrylamide,
2-acrylamido-2-methyl-1-propane sulfonic acid or its salt, and
vinyl acetate.
[0065] Poly (N-alkylacrylamides) include, by way of example,
poly(methacrylamide) and poly(N-isopropyl acrylamide)(PNIPAM).
[0066] Polymers of carboxy vinyl monomers are typically formed from
acrylic acid, methacrylic acid, crotonic acid, isocrotonic acid,
itaconic acid and anhydride, a 1,2-dicarboxylic acid such as maleic
acid or fumaric acid, maleic anhydride, or mixtures thereof, with
preferred hydrophilic polymers within this class including
polyacrylic acid and polymethacrylic acid, with polyacrylic acid
most preferred.
[0067] Preferred hydrophilic polymers herein are the following:
poly(N-vinyl lactams), particularly polyvinyl pyrrolidone (PVP) and
poly(N-vinyl caprolactam) (PVCap); poly(N-vinyl acetamides),
particularly polyacetamide per se; polymers of carboxy vinyl
monomers, particularly polyacrylic acid and polymethacrylic acid;
and copolymers and blends thereof. PVP and PVCap are particularly
preferred.
[0068] The molecular weight of the hydrophilic polymer is not
critical; however, the number average molecular weight of the
hydrophilic polymer is generally in the range of approximately
20,000 to 2,000,000, more typically in the range of approximately
200,000 to 1,000,000.
[0069] The oligomer is "complementary" to the hydrophilic polymers
in that it is capable of hydrogen bonding thereto. Preferably, the
complementary oligomer is terminated with hydroxyl groups, amino or
carboxyl groups. The oligomer typically has a glass transition
temperature T.sub.g in the range of about -100.degree. C. to about
-30.degree. C. and a melting temperature T.sub.m lower than about
20.degree. C. The oligomer may be also amorphous. The difference
between the T.sub.g values the hydrophilic polymer and the oligomer
is preferably greater than about 50.degree. C., more preferably
greater than about 100.degree. C., and most preferably in the range
of about 150.degree. C. to about 300.degree. C. The hydrophilic
polymer and complementary oligomer should be compatible, i.e.
capable of forming a homogeneous blend that exhibits a single
T.sub.g, intermediate between those of the unblended components.
Generally, the oligomer will have a molecular weight in the range
from about 45 to about 800, preferably in the range of about 45 to
about 600. Examples of suitable oligomers include, but are not
limited to, low molecular weight polyalcohols (e.g. glycerol),
oligoalkylene glycols such as ethylene glycol and propylene glycol,
ether alcohols (e.g., glycol ethers), alkane diols from butane diol
to octane diol, including carboxyl-terminated and amino-terminated
derivatives of polyalkylene glycols. Polyalkylene glycols,
optionally carboxyl-terminated, are preferred herein, and
polyethylene glycol having a molecular weight in the range of about
300 to 600 is an optimal complementary oligomer.
[0070] The hydrophilic polymer and the complementary oligomer
should be miscible with respect to each other and have disparate
chain lengths (as may be deduced from the above). The ratio of the
weight average molecular weight of the hydrophilic polymer to that
of the oligomer should be within about 200 and 200,000, preferably
within about 1,250 and 20,000. Also, the polymer and the oligomer
should contain complementary functional groups capable of hydrogen
bonding, ionically bonding, or covalently bonding to each other.
Ideally, the complementary functional groups of the polymer are
located throughout the polymeric structure, while the functional
groups of the oligomer are preferably located at the two termini of
a linear molecule, and are not present along the backbone. Forming
hydrogen bonds or ionic bonds between the two terminal functional
groups of the oligomer and the corresponding functional groups
contained along the backbone of the hydrophilic polymer results in
a noncovalently linked supramolecular network.
[0071] As discussed in co-pending application Ser. No. 09/900,697
for "Preparation of Hydrophilic Pressure Sensitive Adhesives Having
Optimized Adhesive Properties," filed on Jul. 6, 2001 (published as
U.S. patent Publication No. 2002/0037977 on Mar. 28, 2002), the
ratio of the hydrophilic polymer to the complementary oligomer in
the aforementioned blend affects both adhesive strength and the
cohesive strength. As explained in the aforementioned patent
application, the complementary oligomer decreases the glass
transition of the hydrophilic polymer/complementary oligomer blend
to a greater degree than predicted by the Fox equation, which is
given by equation (1) 1 1 T g predicted = w pol T g pol + w pl T g
pl ( 1 )
[0072] where T.sub.g predicted is the predicted glass transition
temperature of the hydrophilic polymer/complementary oligomer
blend, w.sub.pol is the weight fraction of the hydrophilic polymer
in the blend, w.sub.pl is the weight fraction of the complementary
oligomer in the blend, T.sub.g pol is the glass transition
temperature of the hydrophilic polymer, and T.sub.g pl is the glass
transition temperature of the complementary oligomer. As also
explained in that patent application, an adhesive composition
having optimized adhesive and cohesive strength can be prepared
from a hydrophilic polymer and a complementary oligomer by
selecting the components and their relative amounts to give a
predetermined deviation from T.sub.g predicted. Generally, to
maximize adhesion, the predetermined deviation from T.sub.g
predicted will be the maximum negative deviation, while to minimize
adhesion, any negative deviation from T.sub.g predicted is
minimized. Optimally, the complementary oligomer represents
approximately 25 wt. % to 75 wt. %, preferably about 30 wt. % to
about 60 wt. %, of the hydrophilic polymer/complementary oligomer
blend, and, correspondingly, the hydrophilic polymer represents
approximately 75 wt. % to 25 wt. %, preferably about 70 wt. % to
about 40 wt. %, of the hydrophilic polymer/oligomer blend.
[0073] Another general predictor of pressure-sensitive adhesive
behavior in polymers is the .DELTA.C.sub.pT.sub.g product, where
.DELTA.C.sub.p is the change in heat capacity at the polymer
transition point from the glassy to the viscoelastic state. This
product features a measure of the amount of heat that has to be
expended in order to provide the polymer transition from the glassy
to the viscoelastic state and to impart translational mobility to
polymeric segments. As the hydrophilic polymer, e.g., polyvinyl
pyrrolidone, is mixed with the complementary oligomer, e.g.,
PEG-400 occurs, the .DELTA.C.sub.pT.sub.g product decreases,
passing through a minimum that corresponds to the maximum in
adhesion. It is the product .DELTA.C.sub.pT.sub.g which sets the
PSAs apart from non-adhesive polymers (Table 1). The
.DELTA.C.sub.pT.sub.g values, which are associated with the
adhesive PVP-PEG blends and hydrophobic PSA's (PDMS, PIB and
natural rubber), are notably grouped within a narrow area ranging
from 45.0 to 92.0 J/g, predominantly near 65-80 J/g. Non-adhesive
polymers exhibit higher .DELTA.C.sub.pT.sub.g values.
1TABLE 1 Glass transition characteristics of representative
polymers. .DELTA.CpTg Polymer Tg, K .DELTA.Cp, J/gK J/g
Polydimethylsiloxane 150 0.30 45.0 Polyisobuthylene 200 0.40 79.6
Natural rubber 200 0.46 92.0 Polyethylene 237 0.39 92.5 PEG-400 200
0.51 101.4 Bisphenol polycarbonate 415 0.25 103.9 Polymethyl
methacrylate 385 0.29 112.8 Poly(N-vinyl pyrrolidone) 449 0.27
121.2 Polypropylene 253 0.55 139.2 Polystyrene 375 0.38 141.0
Polyvinyl acetate 305 0.50 153.4 Polyethylene terephthalate 340
0.49 165.7 Polyvinyl chloride 355 0.63 229.9
[0074] The .DELTA.C.sub.pT.sub.g value outlines a subtle balance
between free volume and cohesive interactions energy in polymers
(Feldstein et al. (1999), Polym Mater. Sci. Eng. 81:467-468). In
general, the enhanced free volume has to be counterbalanced by a
high attractive interaction energy in order for adhesion to appear.
Enhanced free volume results in high molecular mobility and
liquid-like fluidity of a PSA polymer, whereas substantial cohesive
interaction energy provides cohesive toughness and rubber-like
resistance to flow.
[0075] For certain applications, particularly when high cohesive
strength is desired (such as with pressure-relieving cushions), the
hydrophilic polymer and optionally the complementary oligomer
should be covalently crosslinked. The hydrophilic polymer may be
covalently crosslinked, either intramolecularly or
intermolecularly, and/or the hydrophilic polymer and the
complementary oligomer may be covalently crosslinked. In the former
case, there are no covalent bonds linking the hydrophilic polymer
to the complementary oligomer, while in the latter case, there are
covalent crosslinks binding the hydrophilic polymer to the
complementary oligomer. The hydrophilic polymer, or the hydrophilic
polymer and the complementary oligomer, may be covalently
crosslinked using heat, radiation, or a chemical curing
(crosslinking) agent. The degree of crosslinking should be
sufficient to eliminate or at least minimize cold flow under
compression.
[0076] For covalently crosslinked hydrophilic polymer/complementary
oligomer systems, the oligomer should be terminated at each end
with a group capable of undergoing reaction with a functional group
on the hydrophilic polymer. Such reactive groups include, for
example, hydroxyl groups, amino groups, and carboxyl groups. These
difunctionalized oligomers may be obtained commercially or readily
synthesized using techniques known to those of ordinary skill in
the art and/or described in the pertinent texts and literature.
[0077] For thermal crosslinking, a free radical polymerization
initiator is used, and can be any of the known free
radical-generating initiators conventionally used in vinyl
polymerization. It has now been found that incorporation of an
acrylate-type curing agent typically used for photochemical curing
is also advantageous in the thermal crosslinking of the hydrophilic
polymer/complementary oligomer blend. Such agents include, by way
of example, 1,4-butylene di-methacryl ate or -acrylate; ethylene
di-methacryl ate or -acrylate; trimethylolpropane di- or
tri-acrylate; glyceryl di-acrylate or -methacrylate; glyceryl
tri-acrylate or -methacrylate; glycidyl acrylate or methacrylate;
pentaerythritol triacrylate or trimethacrylate; diallyl phthalate;
2,2-bis(4-methacryloxyphenyl)propane; diallyl adipate;
di(2-acryloxyethyl) ether; dipentaerythritol
monohydroxypentaacrylate; neopentyl glycol diacrylate or
dimethacrylate; polypropylene glycol diacrylate or dimethacrylate;
and 1,3,5-tri-(2-methacryloxyethyl)-s-triaz- ine; and hexamethylene
diacrylate or dimethacrylate.
[0078] Preferred initiators for thermal crosslinking are organic
peroxides and azo compounds, generally used in an amount from about
0.01 wt. % to 15 wt. %, preferably 0.05 wt. % to 10 wt. %, more
preferably from about 0.1 wt. % to about 5% and most preferably
from about 0.5 wt. % to about 4 wt. % of the polymerizable
material. Suitable organic peroxides include those described above
with respect to agents used in connection with curing butyl rubber,
i.e., dialkyl peroxides such as t-butyl peroxide and 2,2
bis(t-butylperoxy)propane, diacyl peroxides such as benzoyl
peroxide and acetyl peroxide, peresters such as t-butyl perbenzoate
and t-butyl per-2-ethylhexanoate, perdicarbonates such as dicetyl
peroxy dicarbonate and dicyclohexyl peroxy dicarbonate, ketone
peroxides such as cyclohexanone peroxide and methylethylketone
peroxide, and hydroperoxides such as cumene hydroperoxide and
tert-butyl hydroperoxide. Suitable azo compounds include azo bis
(isobutyronitrile) and azo bis (2,4-dimethylvaleronitrile). The
temperature for thermal crosslinking will depend on the actual
components and may be readily deduced by one of ordinary skill in
the art, but typically ranges from about 80.degree. C. to about
200.degree. C.
[0079] Crosslinking may also be accomplished with radiation,
typically in the presence of a photoinitator. The radiation may be
ultraviolet, alpha, beta, gamma, electron beam, and x-ray
radiation, although ultraviolet radiation is preferred. Useful
photosensitizers are triplet sensitizers of the "hydrogen
abstraction" type, and include benzophenone and substituted
benzophenone and acetophenones such as benzyl dimethyl ketal,
4-acryloxybenzophenone (ABP), 1-hydroxy-cyclohexyl phenyl ketone,
2,2-diethoxyacetophenone and 2,2-dimethoxy-2-phenylacetophenone,
substituted alpha-ketols such as 2-methyl-2-hydroxypropiophenone,
benzoin ethers such as benzoin methyl ether and benzoin isopropyl
ether, substituted benzoin ethers such as anisoin methyl ether,
aromatic sulfonyl chlorides such as 2-naphthalene sulfonyl
chloride, photoactive oximes such as
1-phenyl-1,2-propanedione-2-(O-ethoxy-carbonyl)-oxime,
thioxanthones including alkyl- and halogen-substituted
thioxanthones such as 2-isopropylthioxanthone,
2-chlorothio-xanthone, 2,4 dimethyl thioxanone, 2,4
dichlorothioxanone, and 2,4-diethyl thioxanone, and acyl phosphine
oxides. Other crosslinking agents suitable for effecting
photocuring include, without limitation, 1,4-butylene
di-methacrylate or -acrylate; ethylene di-methacrylate or
-acrylate; trimethylolpropane di- or tri-acrylate; glyceryl
di-acrylate or -methacrylate; glyceryl tri-acrylate or
-methacrylate; glycidyl acrylate or methacrylate; pentaerythritol
triacrylate or trimethacrylate; diallyl phthalate;
2,2-bis(4-methacryloxyphenyl)-propane; diallyl adipate;
di(2-acryloxyethyl) ether; dipentaerythritol
monhydroxypentaacrylate; neopentyl glycol diacrylate or
dimethacrylate; polypropylene glycol diacrylate or dimethacrylate;
and 1,3,5-tri-(2-methacryloxyethyl)-s-triaz- ine; hexamethylene
diacrylate or dimethacrylate. Radiation having a wavelength of 200
to 800 nm, preferably, 200 to 500 nm, is preferred for use herein,
and low intensity ultraviolet light is sufficient to induce
crosslinking in most cases. However, with photosensitizers of the
hydrogen abstraction type, higher intensity UV exposure may be
necessary to achieve sufficient crosslinking. Such exposure can be
provided by a mercury lamp processor such as those available from
PPG, Fusion, Xenon, and others. Crosslinking may also be induced by
irradiating with gamma radiation or an electron beam. Appropriate
irradiation parameters, i.e., the type and dose of radiation used
to effect crosslinking, will be apparent to those skilled in the
art.
[0080] Suitable chemical curing agents, also referred to as
chemical cross-linking "promoters," include, without limitation,
polymercaptans such as 2,2-dimercapto diethylether,
dipentaerythritol hexa(3-mercaptopropionate), ethylene
bis(3-mercaptoacetate), pentaerythritol
tetra(3-mercaptopropionate), pentaerythritol tetrathioglycolate,
polyethylene glycol dimercaptoacetate, polyethylene glycol
di(3-mercaptopropionate), trimethylolethane
tri(3-mercaptopropionate), trimethylolethane trithioglycolate,
trimethylolpropane tri(3-mercaptopropionate), trimethylolpropane
trithioglycolate, dithioethane, di- or trithiopropane and
1,6-hexane dithiol. The crosslinking promoter is added to the
uncrosslinked hydrophilic polymer to promote covalent crosslinking
thereof, or to a blend of the uncrosslinked hydrophilic polymer and
the complementary oligomer, to provide crosslinking between the two
components.
[0081] The hydrophilic polymer may also be crosslinked prior to
admixture with the complementary oligomer. In such a case, it may
be preferred to synthesize the polymer in crosslinked form, by
admixing a monomeric precursor to the polymer with multifunctional
comonomer and copolymerizing. Examples of monomeric precursors and
corresponding polymeric products are as follows: N-vinyl amide
precursors for a poly(N-vinyl amide) product; N-alkylacrylamides
for a poly(N-alkylacrylamide) product; acrylic acid for a
polyacrylic acid product; methacrylic acid for a polymethacrylic
acid product; acrylonitrile for a poly(acrylonitrile) product; and
N-vinyl pyrrolidone (NVP) for a poly(vinylpyrrolidone) (PVP)
product. Polymerization may be carried out in bulk, in suspension,
in solution, or in an emulsion. Solution polymerization is
preferred, and polar organic solvents such as ethyl acetate and
lower alkanols (e.g., ethanol, isopropyl alcohol, etc.) are
particularly preferred. For preparation of hydrophilic vinyl
polymers, synthesis will typically take place via a free radical
polymerization process in the presence of a free radical initiator
as described above. The multifunctional comonomer include, for
example, bisacrylamide, acrylic or methacrylic esters of diols such
as butanediol and hexanediol (1,6-hexane diol diacrylate is
preferred), other acrylates such as pentaerythritol tetraacrylate,
and 1,2-ethylene glycol diacrylate, and 1,12-dodecanediol
diacrylate. Other useful multifunctional crosslinking monomers
include oligomeric and polymeric multifunctional (meth)acrylates,
e.g., poly(ethylene oxide) diacrylate or poly(ethylene oxide)
dimethacrylate; polyvinylic crosslinking agents such as substituted
and unsubstituted divinylbenzene; and difunctional urethane
acrylates such as EBECRYL.RTM. 270 and EBECRYL.RTM. 230 (1500
weight average molecular weight and 5000 weight average molecular
weight acrylated urethanes, respectively--both available from UCB
of Smyrna, Ga.), and combinations thereof. If a chemical
crosslinking agent is employed, the amount used will preferably be
such that the weight ratio of crosslinking agent to hydrophilic
polymer is in the range of about 1:100 to 1:5. To achieve a higher
crosslink density, if desired, chemical crosslinking is combined
with radiation curing.
[0082] The compositions are self-adhesive and normally do not
require the addition of tackifiers. However, tackifiers may, if
desired, be included. Suitable tackifiers are relatively low
molecular weight resins (weight average molecular weight generally
less than about 50,000) having a fairly high glass transition
temperature. Tackifying resins include, for example, rosin
derivatives, terpene resins, and synthetic or naturally derived
petroleum resins. If tackifiers are incorporated into the present
compositions, preferred tackifying resins are generally selected
from the group of non-polar tackifying resins, such as
Regalrez.RTM. 1085 (a hydrogenated hydrocarbon resin) and
Regalite.RTM. Resins such as Regalite.RTM. 1900, available from
Hercules, Escorez 1304 (also a hydrocarbon resins) and Escorez.RTM.
1102 available from Exxon Chemical Company, Wingtack.RTM. 95 (a
synthetic polyterpene resin), or Wingtack.RTM. 85, available from
Goodyear Tire and Rubber. The resin represents approximately 5 wt.
% to about 15 wt. %, preferably 7.5 wt. % to 12 wt. %, and
preferably 7.5 wt. % to 10 wt. %, relative to the dry adhesive
composition.
[0083] Other components that can be advantageously incorporated
into the adhesive compositions of the invention are, like the
hydrophilic polymer/complementary oligomer blend, water-absorbent
materials. Such components include cellulosic polymers, e.g.,
cellulose esters and analogs, with sodium carboxymethylcellulose
(CMC) and hydroxypropyl cellulose preferred, and with sodium CMC
most preferred. Naturally hydrophilic sorbents may also be used,
e.g., collagens and glycosaminoglycans.
[0084] Incorporation of an antioxidant is optional but preferred.
The antioxidant serves to enhance the oxidative stability of the
composition. Heat, light, impurities, and other factors can all
result in oxidation of the composition. Thus, ideally, antioxidants
should protect against light-induced oxidation, chemically induced
oxidation, and thermally induced oxidative degradation during
processing and/or storage. Oxidative degradation, as will be
appreciated by those in the art, involves generation of peroxy
radicals, which in turn react with organic materials to form
hydroperoxides. Primary antioxidants are peroxy free radical
scavengers, while secondary antioxidants induce decomposition of
hydroperoxides, and thus protect a material from degradation by
hydroperoxides. Most primary antioxidants are sterically hindered
phenols, and preferred such compounds for use herein are tetrakis
[methylene (3,5-di-tert-butyl-4-hydroxy-hydrocinnamate)]methane
(e.g., Irganox.RTM. 1010, from Ciba-Geigy Corp., Hawthorne, N.Y.)
and
1,3,5-trimethyl-2,4,6-tris[3,5-di-t-butyl-4-hydroxy-benzyl]benzene
(e.g., Ethanox.RTM. 330, from Ethyl Corp.). A particularly
preferred secondary antioxidant that may replace or supplement a
primary antioxidant is tris(2,4-di-tert-butylphenyl)phosphite
(e.g., Irgafos.RTM. 168, Ciba-Geigy Corp.). Other antioxidants,
including but not limited to multi-functional antioxidants, are
also useful herein. Multifunctional antioxidants serve as both a
primary and a secondary antioxidant. Irganox.RTM. 1520 D,
manufactured by Ciba-Geigy is one example of a multifunctional
antioxidant. Vitamin E antioxidants, such as that sold by
Ciba-Geigy as Irganox.RTM. E17, are also useful in the present
adhesive compositions. Other suitable antioxidants include, without
limitation, ascorbic acid, ascorbic palmitate, tocopherol acetate,
propyl gallate, butylhydroxyanisole (BHA), butylated hydroxytoluene
(BHT),
bis(1,2,2,6,6-pentamethyl-4-piperidinyl)-(3,5-di-tert-butyl-4-hydroxybenz-
yl)butylpropanedioate, (available as Tinuvin.RTM. 144 from
Ciba-Geigy Corp.) or a combination of octadecyl
3,5-di-tert-butyl-4-hydroxyhydrocinn- amate (also known as
octadecyl 3-(3',5'-di-tert-butyl-4'-hydroxyphenyl)-pr- opionate)
(available as Naugard.RTM. 76 from Uniroyal Chemical Co.,
Middlebury, Conn.) and bis(1,2,2,6,6-pentamethyl-4-piperidinyl
sebacate) (available as Tinuvin.RTM.765 from Ciba-Geigy Corp.).
Preferably, the antioxidant is present in amount up to about 2 wt.
% of the adhesive composition; typically, the amount of antioxidant
is in the range of about 0.05 wt. % to 1.5 wt. %.
[0085] However, other additives may be incorporated into the
present adhesive compositions, so long as they are not detrimental
to the composition in any way. The adhesive composition may also
include conventional additives such as fillers, chain transfer
agents for controlling molecular weight (e.g., carbon tetrabromide,
mercaptans, or alcohols), preservatives, pH regulators, softeners,
thickeners, pigments, dyes, refractive particles, stabilizers,
toughening agents, pharmaceutical agents, and permeation
enhancers.
[0086] Absorbent fillers may be advantageously incorporated to
control the degree of hydration when the adhesive is on the skin or
other body surface. Such fillers can include microcrystalline
cellulose, talc, lactose, kaolin, mannitol, colloidal silica,
alumina, zinc oxide, titanium oxide, magnesium silicate, magnesium
aluminum silicate, hydrophobic starch, calcium sulfate, calcium
stearate, calcium phosphate, calcium phosphate dihydrate, woven and
non-woven paper and cotton materials. Other suitable fillers are
inert, i.e., substantially non-adsorbent, and include, for example,
polyethylenes, polypropylenes, polyurethane polyether amide
copolymers, polyesters and polyester copolymers, nylon and rayon. A
preferred filler is colloidal silica, e.g., Cab-O-Sil.RTM. (Cabot
Corporation, Boston Mass.).
[0087] Preservatives include, by way of example, p-chloro-m-cresol,
phenylethyl alcohol, phenoxyethyl alcohol, chlorobutanol,
4-hydroxybenzoic acid methylester, 4-hydroxybenzoic acid
propylester, benzalkonium chloride, cetylpyridinium chloride,
chlorohexidine diacetate or gluconate, ethanol, and propylene
glycol.
[0088] Compounds useful as pH regulators include, but are not
limited to, glycerol buffers, citrate buffers, borate buffers,
phosphate buffers, or citric acid-phosphate buffers may also be
included so as to ensure that the pH of the adhesive composition is
compatible with that of an individual's body surface.
[0089] Suitable softeners include citric acid esters, such as
triethylcitrate or acetyl triethylcitrate, tartaric acid esters
such as dibutyltartrate, glycerol esters such as glycerol diacetate
and glycerol triacetate; phthalic acid esters, such as dibutyl
phthalate and diethyl phthalate; and/or hydrophilic surfactants,
preferably hydrophilic non-ionic surfactants, such as, for example,
partial fatty acid esters of sugars, polyethylene glycol fatty acid
esters, polyethylene glycol fatty alcohol ethers, and polyethylene
glycol sorbitan-fatty acid esters.
[0090] Preferred thickeners herein are naturally occurring
compounds or derivatives thereof, and include, by way of example:
collagen; galactomannans; starches; starch derivatives and
hydrolysates; cellulose derivatives such as methylcellulose,
hydroxypropylcellulose, hydroxyethyl cellulose, and hydroxypropyl
methylcellulose; colloidal silicic acids; and sugars such as
lactose, saccharose, fructose, and glucose. Synthetic thickeners
such as polyvinyl alcohol, vinylpyrrolidone-vinylacetate-copol-
ymers, polyethylene glycols, and polypropylene glycols may also be
used.
[0091] Low molecular weight plasticizers may also be incorporated
into the composition, including, without limitation, the following:
dialkyl phthalates, dicycloalkyl phthalates, diaryl phthalates and
mixed alkyl-aryl phthalates as represented by dimethyl phthalate,
diethyl phthalate, dipropyl phthalate, di(2-ethylhexyl)phthalate,
di-isopropyl phthalate, diamyl phthalate and dicapryl phthalate;
alkyl and aryl phosphates such as tributyl phosphate, trioctyl
phosphate, tricresyl phosphate, and triphenyl phosphate; alkyl
citrate and citrate esters such as trimethyl citrate, triethyl
citrate, tributyl citrate, acetyl triethyl citrate, and trihexyl
citrate; alkyl adipates such as dioctyl adipate, diethyl adipate,
di(2-methylethyl)adipate, and dihexyl adipate; dialkyl tartrates
such as diethyl tartrate and dibutyl tartrate; alkyl sebacates such
as diethyl sebacate, dipropyl sebacate and dinonyl sebacate; alkyl
succinates such as diethyl succinate and dibutyl succinate; alkyl
glycolates, alkyl glycerolates, glycol esters and glycerol esters
such as glycerol diacetate, glycerol triacetate (triacetin),
glycerol monolactate diacetate, methyl phthalyl ethyl glycolate,
butyl phthalyl butyl glycolate, ethylene glycol diacetate, ethylene
glycol dibutyrate, triethylene glycol diacetate, triethylene glycol
dibutyrate and triethylene glycol dipropionate; and low molecular
weight polyalkylene glycols (molecular weight 300 to 600) such as
polyethylene glycol 400; and mixtures thereof.
[0092] III. Adhesive Compositions Containing an Active Agent:
[0093] Any of the above-described adhesive compositions may be
modified so as to contain an active agent and thereby act as an
active agent delivery system when applied to a body surface in
active agent-transmitting relation thereto. The release of active
agents "loaded" into the present compositions typically involves
both absorption of water and desorption of the agent via a
swelling-controlled diffusion mechanism. Active agent-containing
adhesive compositions may be employed, by way of example, in
transdermal drug delivery systems, in wound dressings, in topical
pharmaceutical formulations, in implanted drug delivery systems, in
oral dosage forms, and the like.
[0094] Suitable active agents that may be incorporated into the
present compositions and delivered systemically (e.g., with a
transdermal, oral, or other dosage form suitable for systemic
administration of a drug) include, but are not limited to:
analeptic agents; analgesic agents; anesthetic agents;
antiarthritic agents; respiratory drugs, including antiasthmatic
agents; anticancer agents, including antineoplastic drugs;
anticholinergics; anticonvulsants; antidepressants; antidiabetic
agents; antidiarrheals; antihelminthics; antihistamines;
antihyperlipidemic agents; antihypertensive agents; anti-infective
agents such as antibiotics and antiviral agents; antiinflammatory
agents; antimigraine preparations; antinauseants; antiparkinsonism
drugs; antipruritics; antipsychotics; antipyretics; antispasmodics;
antitubercular agents; antiulcer agents; antiviral agents;
anxiolytics; appetite suppressants; attention deficit disorder
(ADD) and attention deficit hyperactivity disorder (ADHD) drugs;
cardiovascular preparations including calcium channel blockers,
antianginal agents, central nervous system (CNS) agents,
beta-blockers and antiarrhythmic agents; central nervous system
stimulants; cough and cold preparations, including decongestants;
diuretics; genetic materials; herbal remedies; hormonolytics;
hypnotics; hypoglycemic agents; immunosuppressive agents;
leukotriene inhibitors; mitotic inhibitors; muscle relaxants;
narcotic antagonists; nicotine; nutritional agents, such as
vitamins, essential amino acids and fatty acids; ophthalmic drugs
such as antiglaucoma agents; parasympatholytics; peptide drugs;
psychostimulants; sedatives; steroids, including progestogens,
estrogens, corticosteroids, androgens and anabolic agents; smoking
cessation agents; sympathomimetics; tranquilizers; and vasodilators
including general coronary, peripheral and cerebral. Specific
active agents with which the present adhesive compositions are
useful include, without limitation, anabasine, capsaicin,
isosorbide dinitrate, aminostigmine, nitroglycerine, verapamil,
propranolol, silabolin, foridone, clonidine, cytisine, phenazepam,
nifedipine, fluacizin, and salbutamol.
[0095] For topical drug administration and/or medicated cushions
(e.g., medicated footpads), suitable active agents include, by way
of example, the following:
[0096] Bacteriostatic and bactericidal agents: Suitable
bacteriostatic and bactericidal agents include, by way of example:
halogen compounds such as iodine, iodopovidone complexes (i.e.,
complexes of PVP and iodine, also referred to as "povidine" and
available under the tradename Betadine.RTM. from Purdue Frederick),
iodide salts, chloramine, chlorohexidine, and sodium hypochlorite;
silver and silver-containing compounds such as sulfadiazine, silver
protein acetyltannate, silver nitrate, silver acetate, silver
lactate, silver sulfate and silver chloride; organotin compounds
such as tri-n-butyltin benzoate; zinc and zinc salts; oxidants,
such as hydrogen peroxide and potassium permanganate; aryl mercury
compounds, such as phenylmercury borate or merbromin; alkyl mercury
compounds, such as thiomersal; phenols, such as thymol, o-phenyl
phenol, 2-benzyl-4-chlorophenol, hexachlorophen and
hexylresorcinol; and organic nitrogen compounds such as
8-hydroxyquinoline, chlorquinaldol, clioquinol, ethacridine,
hexetidine, chlorhexedine, and ambazone.
[0097] Antibiotic agents: Suitable antibiotic agents include, but
are not limited to, antibiotics of the lincomycin family (referring
to a class of antibiotic agents originally recovered from
streptomyces lincolnensis), antibiotics of the tetracycline family
(referring to a class of antibiotic agents originally recovered
from streptomyces aureofaciens), and sulfur-based antibiotics,
i.e., sulfonamides. Exemplary antibiotics of the lincomycin family
include lincomycin itself
(6,8-dideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)-carbonyl]amino]-1-thi-
o-L-threo-.alpha.-D-galactooctopyranoside), clindamycin, the
7-deoxy, 7-chloro derivative of lincomycin (i.e.,
7-chloro-6,7,8-trideoxy-6-[[(1-m-
ethyl-4-propyl-2-pyrrolidinyl)carbonyl]-amino]-1-thio-L-threo-.alpha.-D-ga-
lacto-octopyranoside), related compounds as described, for example,
in U.S. Pat. Nos. 3,475,407, 3,509,127, 3,544,551 and 3,513,155,
and pharmacologically acceptable salts and esters thereof.
Exemplary antibiotics of the tetracycline family include
tetracycline itself
4-(dimethylamino)-1,4,4.alpha.,5,5.alpha.,6,11,12.alpha.-octahydro-3,6,12-
,12.alpha.-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide),
chlortetracycline, oxytetracycline, tetracycline, demeclocycline,
rolitetracycline, methacycline and doxycycline and their
pharmaceutically acceptable salts and esters, particularly acid
addition salts such as the hydrochloride salt. Exemplary
sulfur-based antibiotics include, but are not limited to, the
sulfonamides sulfacetamide, sulfabenzamide, sulfadiazine,
sulfadoxine, sulfamerazine, sulfamethazine, sulfamethizole,
sulfamethoxazole, and pharmacologically acceptable salts and esters
thereof, e.g., sulfacetamide sodium.
[0098] Pain relieving agents: Suitable pain relieving agents are
local anesthetics, including, but not limited to, acetamidoeugenol,
alfadolone acetate, alfaxalone, amucaine, amolanone, amylocaine,
benoxinate, betoxycaine, biphenamine, bupivacaine, burethamine,
butacaine, butaben, butanilicaine, buthalital, butoxycaine,
carticaine, 2-chloroprocaine, cinchocaine, cocaethylene, cocaine,
cyclomethycaine, dibucaine, dimethisoquin, dimethocaine, diperadon,
dyclonine, ecgonidine, ecgonine, ethyl aminobenzoate, ethyl
chloride, etidocaine, etoxadrol, .beta.-eucaine, euprocin,
fenalcomine, fomocaine, hexobarbital, hexylcaine, hydroxydione,
hydroxyprocaine, hydroxytetracaine, isobutyl p-aminobenzoate,
kentamine, leucinocaine mesylate, levoxadrol, lidocaine,
mepivacaine, meprylcaine, metabutoxycaine, methobexital, methyl
chloride, midazolam, myrtecaine, naepaine, octacaine, orthocaine,
oxethazaine, parethoxycaine, phenacaine, phencyclidine, phenol,
piperocaine, piridocaine, polidocanol, pramoxine, prilocaine,
procaine, propanidid, propanocaine, proparacaine, propipocaine,
propofol, propoxycaine, pseudococaine, pyrrocaine, risocaine,
salicyl alcohol, tetracaine, thialbarbital, thimylal,
thiobutabarbital, thiopental, tolycaine, trimecaine, zolamine, and
combinations thereof. Tetracaine, lidocaine and prilocaine are
referred pain relieving agents herein.
[0099] Other topical agents that may be delivered using the present
compositions as drug delivery systems include the following:
antifungal agents such as undecylenic acid, tolnaftate, miconazole,
griseofulvine, ketoconazole, ciclopirox, clotrimazole and
chloroxylenol; keratolytic agents, such as salicylic acid, lactic
acid and urea; vessicants such as cantharidin; anti-acne agents
such as organic peroxides (e.g., benzoyl peroxide), retinoids
(e.g., retinoic acid, adapalene, and tazarotene), sulfonamides
(e.g., sodium sulfacetamide), resorcinol, corticosteroids (e.g.,
triamcinolone), alpha-hydroxy acids (e.g., lactic acid and glycolic
acid), alpha-keto acids (e.g., glyoxylic acid), and antibacterial
agents specifically indicated for the treatment of acne, including
azelaic acid, clindamycin, erythromycin, meclocycline, minocycline,
nadifloxacin, cephalexin, doxycycline, and ofloxacin;
skin-lightening and bleaching agents, such as hydroquinone, kojic
acid, glycolic acid and other alpha-hydroxy acids, artocarpin, and
certain organic peroxides; agents for treating warts, including
salicylic acid, imiquimod, dinitrochlorobenzene, dibutyl squaric
acid, podophyllin, podophyllotoxin, cantharidin, trichloroacetic
acid, bleomycin, cidofovir, adefovir, and analogs thereof; and
anti-inflammatory agents such as corticosteroids and nonsteroidal
anti-inflammatory drugs (NSAIDs), where the NSAIDS include
ketoprofen, flurbiprofen, ibuprofen, naproxen, fenoprofen,
benoxaprofen, indoprofen, pirprofen, carprofen, oxaprozin,
pranoprofen, suprofen, alminoprofen, butibufen, fenbufen, and
tiaprofenic acid.
[0100] For wound dressings, suitable active agents are those useful
for the treatment of wounds, and include, but are not limited to
bacteriostatic and bactericidal compounds, antibiotic agents, pain
relieving agents, vasodilators, tissue-healing enhancing agents,
amino acids, proteins, proteolytic enzymes, cytokines, and
polypeptide growth factors. Specific such agents are set forth in
Section IX, infra.
[0101] For topical and transdermal administration of some active
agents, and in wound dressings, it may be necessary or desirable to
incorporate a permeation enhancer into the composition in order to
enhance the rate of penetration of the agent into or through the
skin. Suitable enhancers include, for example, the following:
sulfoxides such as dimethylsulfoxide (DMSO) and
decylmethylsulfoxide (C.sub.10MSO); ethers such as diethylene
glycol monoethyl ether (available commercially as Transcutol.RTM.)
and diethylene glycol monomethyl ether; surfactants such as sodium
laurate, sodium lauryl sulfate, cetyltrimethylammonium bromide,
benzalkonium chloride, Poloxamer (231, 182, 184), Tween (20, 40,
60, 80) and lecithin (U.S. Pat. No. 4,783,450); the 1-substituted
azacycloheptan-2-ones, particularly
1-n-dodecylcyclaza-cycloheptan-2-one (available under the trademark
Azone.RTM. from Nelson Research & Development Co., Irvine,
Calif.; see U.S. Pat. Nos. 3,989,816, 4,316,893, 4,405,616 and
4,557,934); alcohols such as ethanol, propanol, octanol, decanol,
benzyl alcohol, and the like; fatty acids such as lauric acid,
oleic acid and valeric acid; fatty acid esters such as isopropyl
myristate, isopropyl palmitate, methylpropionate, and ethyl oleate;
polyols and esters thereof such as propylene glycol, ethylene
glycol, glycerol, butanediol, polyethylene glycol, and polyethylene
glycol monolaurate (PEGML; see, e.g., U.S. Pat. No. 4,568,343);
amides and other nitrogenous compounds such as urea,
dimethylacetamide (DMA), dimethylformamide (DMF), 2-pyrrolidone,
1-methyl-2-pyrrolidone, ethanolamine, diethanolamine and
triethanolamine; terpenes; alkanones; and organic acids,
particularly salicylic acid and salicylates, citric acid and
succinic acid. Mixtures of two or more enhancers may also be
used.
[0102] IV. Conductive Adhesive Compositions:
[0103] The compositions of the invention can be rendered
electrically conductive for use in biomedical electrodes and other
electrotherapy contexts, i.e., to attach an electrode or other
electrically conductive member to the body surface. For example,
the adhesive composition may be used to attach a transcutaneous
nerve stimulation electrode, an electrosurgical return electrode,
or an EKG electrode to a patient's skin or mucosal tissue. These
applications involve modification of the composition so as to
contain a conductive species. Suitable conductive species are
ionically conductive electrolytes, particularly those that are
normally used in the manufacture of conductive adhesives used for
application to the skin or other body surface, and include
ionizable inorganic salts, organic compounds, or combinations of
both. Examples of ionically conductive electrolytes include, but
are not limited to, ammonium sulfate, ammonium acetate,
monoethanolamine acetate, diethanolamine acetate, sodium lactate,
sodium citrate, magnesium acetate, magnesium sulfate, sodium
acetate, calcium chloride, magnesium chloride, calcium sulfate,
lithium chloride, lithium perchlorate, sodium citrate and potassium
chloride, and redox couples such as a mixture of ferric and ferrous
salts such as sulfates and gluconates. Preferred salts are
potassium chloride, sodium chloride, magnesium sulfate, and
magnesium acetate, and potassium chloride is most preferred for EKG
applications. Although virtually any amount of electrolyte may be
present in the adhesive compositions of the invention, it is
preferable that any electrolyte present be at a concentration in
the range of about 0.1 to about 15 wt. % of the adhesive
composition. The procedure described in U.S. Pat. No.5,846,558 to
Nielsen et al. for fabricating biomedical electrodes may be adapted
for use with the adhesive compositions of the invention, and the
disclosure of that patent is incorporated by reference with respect
to manufacturing details. Other suitable fabrication procedures may
be used as well, as will be appreciated by those skilled in the
art.
[0104] Any absorbent additives incorporated should be compatible
with all components of the hydrogel-containing cushion, and should
also serve to reduce or eliminate cold flow under compression.
Suitable absorbent additives include, by way of example,
polyacrylate starch derivatives, starches, starch copolymers, and
the like.
[0105] V. Fabrication Processes:
[0106] The compositions of the invention are generally prepared by
separately incorporating the necessary curing agents into each
phase, and then blending the phases. That is, the curing agent for
the hydrophobic phase, along with any catalysts or co-curing
agents, are loaded into the composition that will serve as the
hydrophobic phase, and, if applicable, the curing agent for the
hydrophilic phase is loaded into the composition that will serve as
the hydrophilic phase. At this point, the hydrophobic and
hydrophilic compositions are mixed and curing is conducted using
the appropriate means, e.g., radiation or heat.
[0107] VI. Wound Dressings:
[0108] In a further embodiment, the compositions of the invention
are as absorbent materials in a wound dressing. The composition may
be formulated so as to contain a pharmacologically active agent.
Preferred active agents, in this embodiment, include the
bacteriostatic and bactericidal agents, antibiotic agents, and
pain-relieving agents set forth in Section IV, as well as the
following:
[0109] Topical Vasodilators: Such compounds are useful for
increasing blood flow in the dermis, and preferred topical
vasodilators are those known as rubefacients or counterirritants.
Rubefacient agents include nicotinic acid, nicotinates such as
methyl, ethyl, butoxyethyl, phenethyl and thurfyl nicotinate, as
well as the essential oils such as mustard, turpentine, cajuput and
capsicum oil, and components thereof. Particular preferred such
compounds include, but are not limited to, methyl nicotinate,
nicotinic acid, nonivamide, and capsaicin.
[0110] Proteolytic enzymes: Proteolytic enzymes herein are those
that are effective wound cleansing agents, and include, for
example, pepsin, trypsin, collagenase, chymotrypsin, elastase,
carboxypeptidase, aminopeptidase, and the like.
[0111] Peptide, proteins, and amino acids: Suitable peptides and
proteins are tissue-healing enhancing agents (also referred to in
the art as "tissue regenerative agents") such as collagen,
glycosaminoglycans (e.g., hyaluronic acid, heparin, heparin
sulfate, chondroitin sulfate, etc.), proteoglycans (e.g., versican,
biglycan) substrate adhesion molecules (e.g., fibronectin,
vitronectin, laminin), polypeptide growth factors (e.g.,
platelet-derived growth factor, a fibroblast growth factor, a
transforming growth factor, an insulin-like growth factor, etc.),
and other peptides such as fibronectin, vitronectin, osteopontin,
and thrombospondin, all of which contain the tripeptide sequence
RGD (arginine-glycine-aspartic acid), a sequence generally
associated with adhesive proteins and necessary for interaction
with cell surface receptors.
[0112] One embodiment of a wound dressing of the invention is
represented in FIG. 1. The wound dressing is generally indicated at
10, and comprises: an outer backing layer 12 that serves as the
external surface of the dressing following application to the body
surface; a skin contact adhesive layer 14 laminated thereto, which
may or may not be an adhesive composition of the invention,
optionally containing one or more pharmacologically active agents;
an absorbent wound-contacting region 16 comprised of an adhesive
composition of the invention and located on the on the wound
contacting side of layer 14; and a removable release liner 18. Upon
removable of the release liner, the dressing is applied to a body
surface in the region of a wound, and placed on the body surface so
that the wound-contacting region 16 is directly over the wound. In
this embodiment, the wound dressing adheres to the skin surrounding
the wound as a result of the exposed skin contact adhesive areas 20
and 22 surrounding the wound-contacting region. If the
wound-contacting composition is prepared so that it has some degree
of tack prior to absorption of water (as in, e.g., wound exudate),
the dressing adheres in the central region as well. It should be
noted that any of the adhesive compositions of the invention may be
used as a wound dressing herein, providing that, as noted above,
the adhesive composition is substantially nontacky or at most
slightly tacky. Also, those adhesive compositions that exhibit a
high degree of absorbency are preferred. The other components of
the wound dressing of FIG. 1 are as follows:
[0113] The backing layer 12 of the wound dressing functions as the
primary structural element and provides the dressing with
flexibility. The material used for the backing layer should be
inert and incapable of absorbing drug, enhancer or other components
of the wound-contacting adhesive composition. Also, the material
used for the backing layer should permit the device to follow the
contours of the skin and be worn comfortably on areas of skin such
as at joints or other points of flexure, that are normally
subjected to mechanical strain with little or no likelihood of the
device disengaging from the skin due to differences in the
flexibility or resiliency of the skin and the device. Examples of
materials useful for the backing layer are polyesters,
polyethylene, polypropylene, polyurethanes and polyether amides.
The layer is preferably in the range of about 15 microns to about
250 microns in thickness, and may, if desired, be pigmented,
metallized, or provided with a matte finish suitable for writing.
The layer is preferably although not necessarily nonocclusive (or
"breathable"), i.e., is preferably permeable to moisture.
[0114] The skin contact adhesive layer 14 may be composed of a
conventional pressure-sensitive adhesive such as may be selected
from polysiloxanes, polyisobutylenes, polyacrylates, polyurethanes,
polyisobutylene, and the like. Alternatively, the layer may be made
from an adhesive composition of the invention, as described in
Sections II, III and IV, supra.
[0115] Release liner 18 is a disposable element that serves to
protect the device prior to application. The release liner should
be formed from a material impermeable to the drug, vehicle and
adhesive, and that is easily stripped from the contact adhesive.
Release liners are typically treated with silicone or
fluorocarbons, and are commonly made from polyesters and
polyethylene terephthalate.
[0116] In another embodiment, illustrated in FIG. 2, the backing
layer 24 of the wound dressing shown is composed of a tacky or at
least slightly tacky adhesive composition of the invention, but is
provided with a nontacky upper surface 26. The wound-contacting
hydrogel material 28 is adhered to the skin-contacting side of the
backing layer 24. Upon removal of release liner 30, the wound
dressing is applied to an individual's skin in the region of a
wound so that the wound-contacting hydrogel material is placed
directly over the wound. As with the embodiment of FIG. 1, the
wound dressing adheres to the body surface by virtue of the exposed
regions 32 and 34 of the adhesive composition. In this case, it is
preferred that both the backing layer and the adhesive composition
be translucent, so that the extent of wound healing can be viewed
directly through the backing, eliminating the need for frequent
replacement or removal of the wound dressing.
[0117] In a further embodiment, illustrated in FIG. 3, the
perimeter 36 of the wound dressing is made of a different material
than the interior region 38 of the backing. In this case, the
perimeter 36 is comprised of a skin contact adhesive that may or
may not be an adhesive composition of the invention, although the
upper, outwardly facing surface 40 of the perimeter is nontacky.
The interior region 38 of the backing is preferably comprised of an
adhesive composition of the invention. The skin-facing side of the
interior region 38 may or may not be tacky, although the upper
surface 42 of the interior region 38 should be nontacky. The
wound-contacting hydrogel material 44 is adhered to the underside
(i.e., the skin contacting side) of the backing and is centrally
located within interior region 38. As with the embodiment of FIG.
2, it is preferred that both the interior region 38 of the backing
and the wound-contacting hydrogel material 44 are translucent.
Generally, the perimeter adhesive will be opaque. The removable
release liner is indicated at 46. In a variation on the embodiment
of FIG. 3, an outer layer may be laminated to the upper surface of
the device shown. Such an outer layer would then serve as the
actual backing, with the layer represented by interior region 38
and perimeter 36 representing an intermediate layer.
[0118] FIG. 4 is a bottom plan view of the wound dressing of FIG. 3
(with the release liner having been removed), taken along lines
4-4; the view shown is thus the skin-contacting face of the
dressing. As described with respect to FIG. 3, the wound-contacting
hydrogel material 44 is located within the interior region 38 of
the backing, and the perimeter adhesive 36 surrounds that
region.
[0119] In still another embodiment, illustrated in FIG. 5, the
wound dressing contains three layers, a backing layer 48, a central
adhesive layer 50 typically composed of a conventional
pressure-sensitive adhesive, and a wound-contacting hydrogel layer
52, wherein the three layers are coextensive such that there is no
distinct perimeter region as there is in the embodiments of FIG. 1
to 4. During storage and prior to use, the skin contacting side 54
of the dressing is protected with a release liner (not shown), as
above.
[0120] FIG. 6 illustrates a variation of the embodiment of FIG. 5,
wherein the wound dressing is composed of only two layers, a
backing 56 and a wound-contacting hydrogel layer 58 laminated
thereto and coextensive therewith. In this case, the hydrogel layer
58 must have sufficient tack so as to adhere to the backing layer,
even after water absorption. As with the embodiments discussed
above, the skin contacting side 60 is protected with a release
liner (not shown) during storage and prior to use.
[0121] VII. Active Agent Delivery Systems:
[0122] An active agent may be delivered to a body surface by simply
placing a composition of the invention on a body surface in active
agent-transmitting relation thereto. Alternatively, an active
agent-containing composition may be incorporated into a delivery
system or "patch." In manufacturing such systems, the hydrogel
adhesive composition may be cast or extruded onto a backing layer
or release liner and will serve as the skin-contacting face of the
system and act as an active agent reservoir. Alternatively, the
adhesive composition may be used as an active agent reservoir
within the interior of such a system, with a conventional skin
contact adhesive laminated thereto to affix the system to a
patient's body surface.
[0123] Systems for the topical, transdermal or transmucosal
administration of an active agent may comprise: (A) a reservoir
containing a therapeutically effective amount of an active agent;
(B) an adhesive means for maintaining the system in active agent
transmitting relationship to a body surface; and (C) a backing
layer as described in the preceding section, wherein (D) a
disposable release liner covers the otherwise exposed adhesive,
protecting the adhesive surface during storage and prior to use
(also as described in the preceding section). In many such devices,
the reservoir can also serve as the adhesive means, and the
adhesive compositions of the invention can be used as the reservoir
and/or the adhesive means.
[0124] Any number of active agents can be administered using such
delivery systems. Suitable active agents include the broad classes
of compounds normally delivered to and/or through body surfaces and
membranes; such active agents are described in Section V. With some
active agents, it may be necessary to administer the agent along
with a permeation enhancer in order to achieve a therapeutically
effective flux through the skin. Suitable enhancers are also
described in Section IV.
[0125] Accordingly, an active agent-containing composition is
incorporated into the reservoir, either during manufacture of the
system or thereafter. The composition will contain a quantity of an
active agent effective to provide the desired dosage over a
predetermined delivery period. The composition will also contain a
carrier (e.g., a vehicle to solubilize the active agent), a
permeation enhancer, if necessary, and optional excipients such as
colorants, thickening agents, stabilizers, surfactants and the
like. Other agents may also be added, such as antimicrobial agents,
to prevent spoilage upon storage, i.e., to inhibit growth of
microbes such as yeasts and molds. Suitable antimicrobial agents
are typically selected from the group consisting of the methyl and
propyl esters of p-hydroxybenzoic acid (i.e., methyl and propyl
paraben), sodium benzoate, sorbic acid, imidurea, and combinations
thereof.
[0126] Preferably, the delivery system is "monolithic," meaning
that a single layer serves as both the active agent-containing
reservoir and the skin contact adhesive. However, the reservoir and
the skin contact adhesive may be separate and distinct layers.
Also, more than one reservoir may be present, each containing a
different component for delivery into the skin. The present
adhesive compositions may be used as any or all of the
aforementioned layers.
[0127] The backing layer of the drug delivery system functions as
the primary structural element of the transdermal system, and
preferred backing materials in transdermal drug delivery devices
are the same as those described in the preceding section with
respect to wound dressings.
[0128] Additional layers, e.g., intermediate fabric layers and/or
rate-controlling membranes, may also be present in a transdermal
drug delivery system. Fabric layers may be used to facilitate
fabrication of the device, while a rate-controlling membrane may be
used to control the rate at which a component permeates out of the
device. The component may be a drug, a permeation enhancer, or some
other component contained in the drug delivery system.
[0129] In any of these systems, it may be desirable to include a
rate-controlling membrane in the system on the body surface side of
the drug reservoir. The materials used to form such a membrane are
selected to limit the flux of one or more components contained in
the drug formulation, and the membrane may be either microporous or
dense. Representative materials useful for forming rate-controlling
membranes include polyolefins such as polyethylene and
polypropylene, polyamides, polyesters, ethylene-ethacrylate
copolymer, ethylene-vinyl acetate copolymer, ethylene-vinyl
methylacetate copolymer, ethylene-vinyl ethylacetate copolymer,
ethylene-vinyl propylacetate copolymer, polyisoprene,
polyacrylonitrile, ethylene-propylene copolymer,
polysiloxane-polycarbonate block copolymer and the like.
[0130] The compositions of the invention may also serve to deliver
an active agent using other routes of administration. For example,
the compositions may be formulated with excipients, carriers and
the like suitable for oral administration of an orally active drug.
The compositions may also be used in buccal and sublingual drug
delivery, insofar as the compositions can adhere well to moist
surfaces within the mouth. In buccal and sublingual systems,
hydrolyzable and/or bioerodible polymers may be incorporated into
the compositions to facilitate gradual erosion throughout a drug
delivery period. Still other types of formulations and drug
delivery platforms may be prepared using the present compositions,
including implants, rectally administrable compositions, vaginally
administrable compositions, and the like.
[0131] IX. Cushions and Other Products Requiring Adhesion to a Body
Surface:
[0132] The adhesive compositions of the invention are useful in any
number of additional contexts wherein adhesion of a product to a
body surface is called for or desirable. These applications
include, for example, pressure-relieving cushions for application
to a foot, wherein the cushions may or may not contain medication
for transdermal or topical delivery, e.g., in the treatment of
dicubitis, veinous and diabetic foot ulcers, or the like. Suitable
active agents are described in Section IV.
[0133] Such cushions will generally be comprised of a flexible,
resilient outer layer, fabricated from a foam pad or fabric, with a
layer of an adhesive composition of the invention laminated thereto
for application to the skin surface. Suitable cushions include heel
cushions, elbow pads, knee pads, shin pads, forearm pads, wrist
pads, finger pads, corn pads, callus pads, blister pads, bunion
pads and toe pads.
[0134] The compositions of the invention are also useful in a host
of other contexts, e.g., as adhesives for affixing medical devices,
diagnostic systems and other devices to be affixed to a body
surface, and in any other application wherein adhesion to a body
surface is necessary or desired. The adhesive compositions are also
useful as sealants for ostomy devices, prostheses, and face masks,
as sound, vibration or impact absorbing materials, as carriers in
cosmetic and cosmeceutical gel products, and will have other uses
known to or ascertainable by those of ordinary skill in the art, or
as yet undiscovered.
[0135] The practice of the present invention will employ, unless
otherwise indicated, conventional techniques of polymer chemistry,
adhesive manufacture, and hydrogel preparation, which are within
the skill of the art. Such techniques are fully explained in the
literature.
[0136] It is to be understood that while the invention has been
described in conjunction with the preferred specific embodiments
thereof, the foregoing description, as well as the examples that
follow, are intended to illustrate and not limit the scope of the
invention. Other aspects, advantages and modifications will be
apparent to those skilled in the art to which the invention
pertains. All patents, patent applications, journal articles and
other references cited herein are incorporated by reference in
their entireties.
[0137] The following examples are put forth so as to provide those
of ordinary skill in the art with a complete disclosure and
description of how to make and use the compounds of the invention,
and are not intended to limit the scope of what the inventors
regard as their invention. Efforts have been made to ensure
accuracy with respect to numbers (e.g., amounts, temperatures,
etc.) but some errors and deviations should be accounted for.
Unless indicated otherwise, parts are parts by weight, temperature
is in degrees Celsius (.degree. C.), and pressure is at or near
atmospheric.
[0138] The following abbreviations and tradenames are used in the
examples:
[0139] Br-APFR (SP-1055): dibromo-terminated alkyl
phenolformaldehyde resin (Schenectady)
[0140] APFR: alkyl phenolformaldehyde resin (identical to SP-1055
but containing terminol methylol groups) (obtained from M.V.
Lomonosov Moscow State Academy of Fine Chemical Technology)
[0141] BPO: benzoyl peroxide
[0142] BR: butyl rubber, 2 wt. % isoprene content
[0143] HPC: hydroxypropyl cellulose
[0144] PIB: polyisobutylene
[0145] RH: relative humidity
[0146] SR 399: dipentaerythritol monohydroxypentaacrylate
(Sartomer)
EXAMPLE 1
[0147] The following example describe formulation of a
pressure-sensitive adhesive composition based on a cured blend of
polyisobutylene with butyl rubber with PVP-PEG water sorbents, and
optionally with cellulose-based water sorbents, to form a two-phase
adhesive matrix.
[0148] Mixing procedures for the adhesive blend: Two methods of
mixing were used: a laboratory mixer of rotor-plunger type (I) and
a Haake mixer supplied with a sigma-blade and Banbary rotors (II).
With the latter method, a sample is loaded into a working chamber
and heated to the desired temperature, at which point a rotating
agitator was introduced to a predetermined depth to mix the
composition. This procedure was repeated several times to obtain a
homogeneous mixture. The temperature-time regime of mixing depended
on the components used, particularly on the curing agent used.
Usually, mixing may be carried out at a temperature >100.degree.
C. However, if Br-APFR was used as the curing agent, the
temperature was decreased to 60.degree. C. and the curing agent
then added to the PIB-BR blend. The temperature profile was similar
when a Haake mixer was used. The homogeneity of mixing was
established by achieving of a stable level of a torque and
confirmed microscopically by analyzing a pressed adhesive film.
[0149] Pressing and curing adhesive films: The prepared adhesive
blends were pressed between two release liners at an applied
pressure in the range of 1 to 3 MPa. The formulations loaded with
APFR curing agent were hot-pressed at 120.degree. C., whereas the
formulations loaded with SP1055 curing agent and mixed in the Haake
were pressed at room temperature. The adhesive films loaded with
APFR were then cured by annealing in an oven at 160.degree. C. for
one hour. The adhesive films loaded with SP1055 were cured at
120.degree. C. for 30 minutes.
[0150] Patch preparation: The cured adhesive films were laminated
to PU backing film with subsequent die cutting of the patches. The
thickness of the adhesive layer in the obtained patches varied from
350 to 700 .mu.m. To provide a gradual decrease of adhesive layer
thickness toward patch edges, pressing molds were designed and
constructed with the thickness of central part .about.500-700 .mu.m
and peripheral part of 100-200 .mu.m.
[0151] Preparation of the hydrophobic phase: The hydrophobic phase
was prepared by blending PIB with BR. Although neither PIB nor BR
is a good adhesive, mixing the two results in enhancement of
adhesive properties within a wide concentration range, as indicated
in FIG. 7. That figure gives the peel strength data obtained for a
PIB/BR blends at a range of PIB:BR ratios. As the maximum peel
strength was observed with a blend containing 40% of PIB and 60%
BR, that composition was used as a basis for preparation of an
adhesive composition according to the invention. In FIG. 7, Curve A
was produced by tenfold PIB-BR film pressing at a compression
stress of 1-2 MPa and a temperature of 120.degree. C., while Curve
B was produced by mixing with a high speed mixer at a temperature
of 170.degree. C. for 20 minutes prior to curing the adhesive film.
To obtain cohesive strength (e.g., for cushions and other
pressure-relieving or weight-bearing applications), the PIB-BR
blend should be cured. Since PIB contains no double bonds and
cannot be crosslinked, curing g the PIB-BR blends is made possible
via BR crosslinking.
EXAMPLE 2
[0152] Curing a PVP-PEG hydrogel dispersed within the hydrophobic
polymer:
[0153] Cured PVP-PEG hydrogels were found to be highly hygroscopic.
At relatively low degrees of hydration, these hydrogels provide
adhesive and viscoelastic properties that allow them to be used for
SCA matrices in cushion patches. If, however, such hydrogels absorb
more than about 15% water, they swell so much that they become
unsuitable for cushion usage. In order to decrease the PVP-PEG
hydrogel hygroscopicity, it was found useful to mix the hydrogel
with an appropriate hydrophobic adhesive. The following
experimental work was carried out to determine conditions under
which such mixtures can be cured so that they become viscoelastic
at room temperature and have adhesive properties suitable for use
in cushion pads. In these experiments, a PVP-PEG hydrogel was mixed
with a PIB-BR-Regalite adhesive. UV-curing to produce PVP-PEG
crosslinking, employing dipentaerythritol monohydroxy pentaacrylate
SR 399 (Sartomer) as curing agent and benzoyl peroxide (BPO) as an
initiator of radical polymerization, was implemented at elevated
temperatures. The results of these experiments are shown in FIG. 8.
In FIG. 8, the indivudal curves are as follows--1: SR/PVP weight
ratio is 5, T=100.degree. C. 2: SR/PVP=5, 90.degree. C. 3:
SR/PVP=2, 105.degree. C. 4: SR/PVP=2, 95.degree. C. As can be seen
in this figure, crosslinking was found to start at about 80.degree.
C. At relatively high SR 399 loading, the curing took about 15 min,
both at 90 and 100.degree. C. At lower curing agent concentrations,
the crosslinking took longer, whereas an increase in temperature
accelerated the curing significantly. The maximum achieved level of
shear stress, which relates to the blend viscosity and crosslinking
density, was found to be nearly independent of the SR 399/PVP
ratio.
[0154] Next, experiments were performed in which the PVP-PEG
hydrogel, with or without curing agent SR 399, was mixed with
PIB-BR-Regalite hydrophobic adhesive, with or without APFR as a
curing (crosslinking) agent. The mixtures were cured at 160.degree.
C. As shown in FIG. 9, curing only occurred if both phases
(hydrophobic and hydrophilic) contained their relevant
crosslinkers. In FIG. 9, the first [+] or [-] sign refers to the
presence or absence of curing agent in the hydrophobic phase, while
the second [+] or [-] sign refers to the presence or absence of
curing agent in the hydrophilic phase. In order for the mixture to
cure and blend properly, each phase (hydrophobic and hydrophilic)
had to be loaded with its relevant crosslinker prior to mixing.
EXAMPLE 3
[0155] Adhesive properties of PIB-BR blends with hydrophilic
sorbents:
[0156] As shown in FIG. 10, mixing of a hydrophobic adhesive with
40% or more of a nonadhesive hydrophilic sorbent resulted in a
gradual decrease of adhesion. If, however, the hydrophilic phase
was the adhesive PVP-PEG hydrogel, the blending was not accompanied
by a loss of adhesion. This trend was found to be typical of any
hydrophobic adhesive and hydrophilic sorbent.
EXAMPLE 4
[0157] Effects of blending with hydrophilic sorbents on the
viscoelastic behavior of hydrophobic adhesives:
[0158] To determine the viscoelastic properties of various
two-phase adhesives, retardation analysis was employed, based on
Equation 2: 2 J ( t ) = t 1 o + 1 i J i [ - ( t - t 1 ) ] i ( 2
)
[0159] In this equation, the recovery response of a viscoelastic
sample can be described in terms of the compliance J(t), which is
expressed as a function of retardation times .lambda.i, where i=1,
2, 3 etc., .eta..sub.0 is an instantaneous dynamic viscosity (the
material constant characterizing the resistance of a liquid against
being forced to flow), and t.sub.i is a measurement time. For
infinite time (t) all e-functions become zero and thus the equation
reduces to J(t=.infin.)=t.sub.1/.eta..s- ub.0, which equals the
permanent strain, i.e. the amount of viscous squeezing flow of the
sample. For t.sub.1=0 and J.sub.2,3 . . . =0 the function (2)
matches the Kelvin-Voigt model. The retardation analysis was
performed using the Microcal Origin software with a three-term
model J.sub.eq(t)=J.sub.0+J.sub.1+J.sub.2, where J.sub.eq(t) is the
equilibrium retardation compliance (reciprocal of equilibrium
retardation modulus).
[0160] The results, presented in Table 2, are in a close agreement
with those obtained using the Kelvin-Voigt model. The present data
are highly informative regarding the relaxation properties of the
various components of the adhesive materials.
2TABLE 2 Results of retardation analysis of several two-phase
adhesives using Equation 2 Squeezing Composition force, N J.sub.o,
Pa.sup.-1 J.sub.1 J.sub.2 J.sub.eq G.sub.eq, Pa .lambda..sub.1, sec
.lambda..sub.2 PIB-BR (1:1) + 0.5 5.94 10.sup.-6 1.68 10.sup.5 100
5% APFR, 1 3.14 10.sup.-6 3.19 10.sup.5 106 uncured 5 6.27
10.sup.-7 1.6 10.sup.6 106 PIB-BR (1:1) + 0.5 8.3 10.sup.-6 9
10.sup.-6 1.73 10.sup.-5 5.78 10.sup.4 2.7 10.sup.-10 213 5% APFR,
1 6.58 10.sup.-6 3.43 10.sup.-6 1 10.sup.-5 1.10.sup.5 1 10.sup.-16
812 cured 5 4.7 10.sup.-6 1 10.sup.-5 1.47 10.sup.-5 6.8 10.sup.4
268 1185 PIB 70% + 0.5 8.53 10.sup.-7 1.17 10.sup.6 45 HPC 30% 1
4.67 10.sup.-7 2.14 10.sup.6 45 5 3.17 10.sup.-6 3.15 10.sup. 33
PIB-BR 0.5 1.3 10.sup.-12 7.65 10.sup.-7 1.32 10.sup.-6 2 10.sup.-6
5 10.sup.5 0.0001 124 (40:60) + 30% - 1 1.8 10.sup.-24 3.87
10.sup.-7 1.2 10.sup.-6 1.6 10.sup.-6 6.25 10.sup.5 11.27 250 HPC 5
1.9 10.sup.-9 4.4 10.sup.-7 3.5 10.sup.-7 7.9 10.sup.-7 1.26
10.sup.6 30 540 50% (PIB 0.5 4.61 10.sup.-8 5.96 10.sup.-6 5.38
10.sup.-6 1.13 10.sup.-6 8.82 10.sup.4 42 611 30% + BR 1 0 2.9
10.sup.-6 3.6 10.sup.-6 6.5 10.sup.-6 1.5 10.sup.5 160 955 40% +
Regalite 5 0 4.43 10.sup.-7 2.26 10.sup.6 564 30%) + 50% PVP-PEG
(64/36)
[0161] The low J.sub.0 values found for the cured systems, and the
blends containing HPC, are a sign of negligible flow contribution.
It is important to note that HPC has been found to depress
dramatically the squeezing flow of PIB and PIB-BR mixtures, whereas
it has a weaker effect on other adhesives, e.g., DuraTak
adhesives.
* * * * *